

Circulation

Cardiovascular function and treatment in β -thalassemia major: a consensus statement from the American Heart Association

Dudley J. Pennell, MD, FRCP, FAHA, Co-Chair; James E. Udelson, MD, FAHA, Co-Chair; Andrew E. Arai, MD, FAHA; Biykem Bozkurt, MD, PhD, FAHA; Alan R. Cohen, MD; Renzo Galanella, MD†; Timothy M. Hoffman, MD, FAHA; Michael S. Kiernan, MD; Stamatios Lerakis, MD, FAHA; Antonio Piga, MD; John B. Porter, MD; John Malcolm Walker, MD; John Wood, MD, PhD; on behalf of the American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging

CIRCULATION



Cardiovascular Function and Treatment in β -Thalassemia Major

A Consensus Statement From the American Heart Association

Endorsed by the Thalassaemia International Federation, European Society of Cardiology Working Group on Cardiovascular Magnetic Resonance, and Society for Cardiovascular Magnetic Resonance

Dudley J. Pennell, MD, FRCP, FAHA, Co-Chair; James E. Udelson, MD, FAHA, Co-Chair;
Andrew E. Arai, MD, FAHA; Biykem Bozkurt, MD, PhD, FAHA; Alan R. Cohen, MD;
Renzo Galanello, MD[†]; Timothy M. Hoffman, MD, FAHA; Michael S. Kiernan, MD;
Stamatios Lerakis, MD, FAHA; Antonio Piga, MD; John B. Porter, MD; John Malcolm Walker, MD;
John Wood, MD, PhD; on behalf of the American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging

Abstract—This aim of this statement is to report an expert consensus on the diagnosis and treatment of cardiac dysfunction in β -thalassemia major (TM). This consensus statement does not cover other hemoglobinopathies, including thalassemia intermedia and sickle cell anemia, in which a different spectrum of cardiovascular complications is typical. There are considerable uncertainties in this field, with a few randomized controlled trials relating to treatment of chronic myocardial siderosis but none relating to treatment of acute heart failure. The principles of diagnosis and treatment of cardiac iron loading in TM are directly relevant to other iron-overload conditions, including in particular Diamond-Blackfan anemia, sideroblastic anemia, and hereditary hemochromatosis.

Heart failure is the most common cause of death in TM and primarily results from cardiac iron accumulation. The diagnosis of ventricular dysfunction in TM patients differs from that in nonanemic patients because of the cardiovascular adaptation to chronic anemia in non-cardiac-loaded TM patients, which includes resting tachycardia, low blood pressure, enlarged end-diastolic volume, high ejection fraction, and high cardiac output. Chronic anemia also leads to background symptomatology such as dyspnea, which can mask the clinical diagnosis of cardiac dysfunction. Central to early identification of cardiac iron overload in TM is the estimation of cardiac iron by cardiac T2* magnetic resonance. Cardiac T2* <10 ms is the most important predictor of development of heart failure. Serum ferritin and liver iron concentration are not adequate surrogates for cardiac iron measurement. Assessment of cardiac function by noninvasive techniques can also be valuable clinically, but serial measurements to establish trends are usually required because interpretation of single absolute values is complicated by the abnormal cardiovascular hemodynamics in TM and measurement imprecision.

Acute decompensated heart failure is a medical emergency and requires urgent consultation with a center with expertise in its management. The first principle of management of acute heart failure is control of cardiac toxicity related to free iron by urgent commencement of a continuous, uninterrupted infusion of high-dose intravenous deferoxamine, augmented by

[†]Deceased.

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on April 4, 2013. A copy of the document is available at <http://my.americanheart.org/statements> by selecting either the “By Topic” link or the “By Publication Date” link. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com.

This consensus statement was reviewed and endorsed by the ESC Working Group on Cardiovascular Magnetic Resonance, at the request of the American Heart Association. Although there is agreement with the general concepts of this document and confidence in the methodology used by the American Heart Association, the ESC Working Group on Cardiovascular Magnetic Resonance may not agree with every identified statement and/or specific wording. This document was not published by the ESC Working Group on Cardiovascular Magnetic Resonance and is not considered official ESC policy.

The American Heart Association requests that this document be cited as follows: Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, Hoffman TM, Kiernan MS, Lerakis S, Piga A, Porter JB, Walker JM, Wood J; on behalf of the American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging. Cardiovascular function and treatment in β -thalassemia major: a consensus statement from the American Heart Association. *Circulation*. 2013;128:281–308.

Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit <http://my.americanheart.org/statements> and select the “Policies and Development” link.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.heart.org/HEARTORG/General/Copyright-Permission-Guidelines_UCM_300404_Article.jsp. A link to the “Copyright Permissions Request Form” appears on the right side of the page.

oral deferiprone. Considerable care is required to not exacerbate cardiovascular problems from overuse of diuretics or inotropes because of the unusual loading conditions in TM.

The current knowledge on the efficacy of removal of cardiac iron by the 3 commercially available iron chelators is summarized for cardiac iron overload without overt cardiac dysfunction. Evidence from well-conducted randomized controlled trials shows superior efficacy of deferiprone versus deferoxamine, the superiority of combined deferiprone with deferoxamine versus deferoxamine alone, and the equivalence of deferasirox versus deferoxamine. (*Circulation*. 2013;128:281-308.)

Key Words: AHA Scientific Statement ■ CT and MRI ■ heart failure ■ other heart failure ■ other treatment ■ thalassemia

1. Introduction

1.1 Need for Consensus Document

Heart disease has been the predominant cause of death in β -thalassemia major (TM) in cohort studies.¹⁻⁴ Significant advances in the identification and risk stratification of patients with myocardial siderosis have occurred since 2001 with magnetic resonance (MR) technology,⁵⁻⁷ and with this, it has been possible to focus on the heart as the target lethal organ in TM and tailor chelation treatment and prevention accordingly.⁸⁻¹⁰ There is evidence that this approach has contributed to the significant reduction in cardiac mortality in TM.^{3,11-14} These advances give room for a consensus document in a rapidly evolving field in both diagnostics and therapeutics. The aim of the present document is to bring together broad-ranging cardiological and hematologic experience in the heart and heart failure (HF) in TM, summarize how to measure cardiac iron and function, identify and treat patients at high risk to prevent HF, and diagnose and treat HF. A primary premise of this review document is that cardiac disease is easier and safer to treat at an early stage rather than a late stage when the hazard of death is high. We build on previous, more focused summary reviews and consensus statements on the heart in TM¹⁵⁻²⁰ and build a consensus of the assessment of cardiac function and treatment of HF in TM.

2. Fundamentals of TM and the Heart

2.1 Iron-Loading Conditions

2.1.1 β -Thalassemia Major

TM is a genetic condition with severe reduction or absent production of the β -globin chain constituent of hemoglobin (Hb) A. This results in ineffective erythropoiesis caused by an excess of α -globin chains and profound anemia that is life-threatening from ≈ 1 to 2 years of age. Blood transfusions are required lifelong; however, the iron load of ≈ 200 mg per unit combined with mildly increased gastrointestinal iron uptake related to hepcidin suppression²¹ increases total body iron, which leads to a requirement for lifelong iron chelation treatment to prevent or reverse iron-related complications. A broad phenotypic characterization of TM is the requirement for >8 transfusion events per year (may have multiple units at each transfusion) in an adult aged >16 years.²² TM varies greatly in frequency around the world, being most prevalent in areas with endemic population exposure to malaria (Asia, the Middle East, Mediterranean Europe), and this is considered to

have created positive pressure for the accumulation of hemoglobin genetic mutations that in heterozygote form provide innate resistance to parasitization by plasmodia of red cells. In countries with no historical exposure to endemic malaria, TM occurs through immigration. Thus, the United States and the United Kingdom each have <1000 TM patients, whereas Indonesia has many thousands of registered TM patients with likely high levels of underreporting.

2.1.2 Thalassemia Intermedia

The cardiovascular manifestations of thalassemia intermedia are beyond the scope of this document but typically include a greater propensity to pulmonary hypertension and thrombosis.^{23,24} In thalassemia intermedia, there is a very variable increase in gastrointestinal iron uptake. Patients with thalassemia intermedia generally do not require transfusions to maintain the hemoglobin level and form part of the spectrum of non-transfusion-dependent thalassemia, which also includes other genotypes, such as some patients with E- β -thalassemia and HbH disease. As patients with thalassemia intermedia get older, however, they may require transfusions to prevent complications, including those in the cardiovascular system. This leads to iron loading and an increased requirement for iron chelation.

2.1.3 Sickle Cell Anemia

The cardiovascular manifestations of sickle cell anemia are beyond the scope of this document but typically include a greater propensity to sickle cell crisis (severe generalized attacks of pain), as well as pulmonary hypertension, thrombosis, and stroke.²⁵ Patients with sickle cell anemia are increasingly being transfused to prevent cardiovascular complications, which leads to iron loading and an increased requirement for iron chelation. Although the risks of extrahepatic iron deposition and organ toxicity are lower in sickle cell anemia than in other transfusional anemias, they increase proportionally to the duration of chronic transfusion therapy.

2.1.4 Other Iron-Loading Conditions

There are other causes of iron overload, including conditions such as hereditary hemochromatosis, Diamond-Blackfan anemia, sideroblastic anemia, myelodysplasia, and α -thalassemia, for which these guidelines are relevant but for which the evidence base is lower than for TM. Patients

with transfusion-dependent Diamond-Blackfan anemia and sideroblastic anemia appear to be at particularly high risk for extrahepatic iron deposition and toxicity.

2.2 Aims of Transfusion in TM

The main aim of blood transfusion in TM, beyond prolonging life, is the suppression of ineffective erythropoiesis. To achieve this, clinical experience and guidelines²⁶ suggest that maintaining a pre-transfusion hemoglobin level of 9 to 10 g/dL with a posttransfusion hemoglobin level of 13 to 14 g/dL leads to a balance between minimization of iron loading and maximization of symptom relief. Transfusions reduce the expansion of blood volume seen in chronic anemia, which is a driver of increased cardiac index.

2.3 Cause of Death in TM

Before the introduction of chelation, the most common cause of death in TM patients receiving regular transfusions in the 1960s was HF.²⁷ In the era of deferoxamine iron chelation, mortality was postponed considerably, but mortality from cardiac iron overload continued to dominate the causes of death, accounting for $\approx 70\%$ of cases.^{1,2,28,29}

2.4 Age at Cardiac Death

The age of cardiac death in TM depends on a number of factors, including access to transfusions and chelation. In transfused but unchelated patients, the typical age at death was 10 years, primarily of cardiac causes.³⁰ With the introduction of deferoxamine treatment in the late 1970s, the median age of survival improved and was strongly dependent on birth cohort. In the United Kingdom, by the year 2000, the median age at death was 35 years.² Improvements in survival with deferoxamine treatment by later birth cohort have been confirmed in other countries.^{3,31,32}

2.5 Frequency of Cardiac Iron Overload

Samples of TM patients in a number of countries across the world have shown cardiac iron overload to be common using definitions from T2* cardiovascular magnetic resonance (CMR) of severe cardiac iron loading of <10 ms and mild to

moderate cardiac iron loading of 10 to 20 ms (refer to Section 3.3 for measurement of iron by T2* CMR; Table 1).

2.6 Frequency of Cardiomyopathy

There are 2 ways by which cardiomyopathy prevalence can be measured. The first is by prevalence of the clinical syndrome of HF. The prevalence varies by patient age and by year of birth. In a cohort of 97 patients born before 1976, 37% had heart disease, as defined by need for inotropic or antiarrhythmic medications.²⁸ In a US survey in 2004, the number of TM patients of all ages receiving cardiac medication was found to be 10% (35/341).²² In an Italian cohort, the prevalence of HF by 15 years of age was 5% in patients born between 1970 and 1974 and 2% in those born between 1980 and 1984.⁴² In a worldwide survey conducted in 2012, the incidence of HF at first T2* scan was 3.1% (107/3445).⁴¹ Alternatively, the prevalence of detectable left ventricular (LV) dysfunction is higher than the prevalence of clinically manifest HF. In one study of 167 Italian patients, LV dysfunction was found in 19 patients (11.4%).³⁸ Another more recent Italian study found a high prevalence of LV dysfunction of 19%. This higher figure may represent the high prevalence of hepatitis C infection⁴³ and aging of the Italian TM population compared with clinical experience elsewhere.

2.7 HF and Survival

The natural history and clinical course in untreated patients is one of clinically silent myocardial iron accumulation for many years, followed by malignant arrhythmias and acutely impaired myocardial function in early adulthood.^{27,44} The time from symptom appearance to death was short, typically approximately 6 to 12 months. With improved access to iron chelation in the 1970s, life expectancy improved, with patients expected to survive to their mid-30s^{28,31,45}; however, 5-year survival for patients presenting in HF (ages 24 ± 5 years) was only 48%.⁴⁶ These data were disconcerting given the ample evidence that intensive iron chelation therapy could completely restore cardiac function in most patients with preclinical dysfunction and some with overt HF.^{47–49} The clearance of cardiac iron substantially lagged improvements in systolic function,⁴⁷ which explains the high risk of relapse observed with premature termination of intensive chelation therapy.^{48,49} Recognition of severe cardiac siderosis by T2* CMR and intervention with suitable treatment, before the onset of symptomatic HF, is associated with improvements in ventricular function.⁵⁰ As a result, recent improvements in life expectancy for TM patients in the United Kingdom can be explained by the increasing availability of T2* CMR and earlier escalation of therapy.^{11,51} The acute mortality of New York Heart Association stage IV HF in thalassemia remains high (probably in excess of 50% in hospital mortality) simply because support for the heart and other failing organs, especially the kidneys and liver, often cannot be continued long enough for iron chelation to stabilize myocardial function, a process that may take many months. Nonetheless, futility cannot be predicted, and intensive chelation and prolonged cardiopulmonary support should be attempted in all patients with iron cardiomyopathy, because survival to an excellent

Table 1. Frequency of Cardiac Iron Overload

Country	Sample Size, n	Frequency, %		
		Severe: T2* <10 ms	Mild to Moderate: T2* >10 –20 ms	Normal: T2* >20 ms
United Kingdom ⁵	109	20	43	37
Hong Kong ³³	180	26	24	50
Turkey ³⁴	28	46	39	14
Australia ³⁵	30	37	27	37
Oman ³⁶	81	24	22	54
United States ³⁷	141	13	21	66
Italy ³⁸	167	13 (<8 ms)	52 (8–20 ms)	35
Italy ³⁹	220	30% <20 ms		66
Greece ⁴⁰	159	68% <20 ms		32
Worldwide survey ⁴¹	3445	20	22	58

quality of life may be achieved in a significant proportion of patients.

2.8 Age, Transfusions, and Cardiac Loading

There are few data relating the age of onset of cardiac iron loading with age and transfusion history. Among patients with myelodysplasia who received transfusions but no chelation, those with cardiac T2* <20 ms had received >100 U of blood.⁵² In children with hemoglobinopathy who received transfusion and chelation, the cardiac T2* was <20 ms only after 10 years of age.^{53,54} However, occasional younger onset of cardiac iron, as young as 7 years, has been recorded in TM, especially when access to chelation is limited.⁵⁵

2.9 Cardiac Uptake of Iron

There is an incomplete understanding of iron loading into the heart, and no studies have been performed in humans. Cell and animal studies have indicated that cardiac entry of iron is mediated by the divalent metal transporter 1 (DMT1) and L-type calcium channels,^{56,57} as well as the T-type calcium channels,⁵⁸ although another pathway may be involved for ferric (Fe)³⁺ ions.⁵⁹ Non-transferrin-bound iron uptake has been shown to be rapid in isolated cardiomyocytes.⁶⁰ Nifedipine was shown to hinder iron uptake into cardiac cells, and this therapeutic possibility is being explored in a pilot study in humans.⁶¹ Anecdotal evidence from individual cases⁶² and family studies of discrepant cardiac iron loading, as well as evidence from a worldwide survey of cardiac T2*,⁴¹ suggests that genetic modifiers of cardiac iron uptake may be present and clinically relevant. The only genetic influence known to date is the glutathione S-transferase-M1 (GSTM1) null genotype, which was associated with an increased level of cardiac iron.^{63,64} GSTM1 has also been implicated in liver iron loading.⁶⁵

2.10 Cardiac Pathophysiology in TM

In untreated TM, chronic profound anemia causes high-cardiac-output HF and is fatal at a young age. The early start of regular transfusion prevents early cardiac death and other complications of anemia but results in progressive iron accumulation toxicity. In the heart, increased levels of intracellular free iron are toxic through a number of mechanisms,^{66,67} including (1) damage to membranes by lipid peroxidation; (2) damage to mitochondria and the respiratory enzyme chain^{68,69}; (3) interference with electrical function, including ryanodine release channel interference^{70,71}; (4) promotion of cardiac fibrosis, which was prominently reported in early autopsy studies,⁷² although it is rare with greater access to chelation⁷³; and (5) altered gene expression.⁷⁴

2.11 Adaptive Cardiac Physiology in TM in Absence of Cardiac Iron Loading

Because hemoglobin is responsible for oxygen transport, to preserve oxygen delivery, the body compensates for low hemoglobin levels by increasing the cardiac output and cardiac index, which is the cardiac output normalized to body surface area, up to 60% compared with normal control subjects. The increased cardiac index is usually achieved by an increase

in end-diastolic volume, stroke volume, and heart rate. TM therefore represents a chronic high-output state produced by volume-loaded ventricles (high preload). To maintain normal systemic blood pressure in the presence of high cardiac output, the body has to lower the systemic vascular resistance through peripheral arterial vasodilation, which leads to wide pulse pressures and low diastolic blood pressure.^{70,75,76} The increased cardiac output may lead to flow murmurs on cardiac auscultation. The ejection fraction is increased because of decreased afterload and increased preload.

2.12 Clinical Cardiac Manifestations of Iron Overload

In the absence of regular iron chelation, historical series show a broad range of cardiac complications, including pericarditis, myocarditis, HF, and arrhythmias.^{27,72} In the modern era, with iron chelation treatment, the clinical manifestation of cardiac disease has changed, and pericarditis and myocarditis are now rare. Historical postmortem studies showed severe replacement cardiac fibrosis,^{27,72} but this is now rare in more modern cohorts of patients dying of HF.⁷³ More minor patches of myocardial fibrosis have been identified in vivo with late gadolinium-enhancement CMR in Italian patients with TM,⁷⁷ but this has not been reproduced in the United Kingdom.⁷⁸ This difference probably results from higher levels of myocarditis resulting from hepatitis C infection in Italy.⁷⁹ The most common clinical manifestations of cardiac disease are now dilated cardiomyopathy (with restrictive features) and arrhythmia, predominantly atrial fibrillation (AF). In severe cardiac iron loading, ventricular arrhythmias become more common, and ectopic atrial tachycardia, flutter, and chaotic atrial rhythms may also occur. Recent autopsy data show that iron deposition in the myocardium in TM patients occurs preferentially in the subepicardium, no systematic variation occurs between myocardial regions, and iron in the interventricular septum is highly representative of total cardiac iron.⁷ Some authors advocate use of multislice T2* data to characterize heterogeneity in myocardial iron distribution, but this technique requires corrections for large, patient-specific magnetic susceptibility artifacts. Although global sampling of cardiac T2* potentially offers a more complete picture of cardiac iron burden, anatomic correlations for this approach are lacking.³⁹ Other relevant iron-overload complications that may affect the heart include hypothyroidism, diabetes mellitus, hypoadrenalism, growth hormone deficiency, and hypoparathyroidism.

Changes in the heart in addition to ventricular systolic impairment include the following: (1) Decreased left atrial function, which is attributable to ventricular stiffening or direct atrial toxicity. Limited data suggest that decreased left atrial function is a more sensitive marker of iron toxicity than left ventricular ejection fraction (LVEF),^{76,80} but further data are needed. (2) Impaired right ventricular (RV) function, which may be caused by the increased vulnerability of the RV to the effects of iron deposition because of its thin wall. Tissue Doppler imaging velocity and strain imaging suggest early RV impairment in iron overload.⁸¹ (3) Impaired endothelial function in iron overload.^{9,82–84} Improvement in

endothelial function has been documented with deferiprone⁹ and deferasirox.⁸³ (4) Impaired diastolic function as shown by tissue Doppler imaging has been reported with cardiac iron overload, but only in small studies, and its low sensitivity limits its use for diagnosis and as a prognostic tool.^{85,86} Impaired diastolic function shown by CMR also had low sensitivity for identification of cardiac iron loading.⁸⁷

2.13 Vascular Effects of Iron Loading

Patients with TM and normal cardiac iron levels documented by T2* and no clinical signs of cardiac dysfunction have increased aortic stiffness as assessed by pulse-wave velocity (carotid-femoral) and augmentation index compared with normal control subjects.⁸⁸

3. Diagnostic Strategies for Cardiac Involvement in TM

3.1 Basic Tests

New-onset electrocardiographic abnormalities are usually evident in TM patients with HF⁸⁹ and may include supraventricular arrhythmias, electrocardiographic findings that suggest right-sided heart involvement (S₁Q₃ pattern and right-axis deviation), new-onset T-wave inversion beyond lead V₁, and a consistent decrease in QRS height. In patients without HF, an abnormal ECG was found in 46% (T-wave abnormalities in 34% and right bundle-branch block in 12%), which was weakly associated with lower myocardial T2* and mild myocardial fibrosis, probably from hepatitis C myocarditis.⁹⁰ Electrocardiographic changes most specifically associated with cardiac iron include repolarization abnormalities and relative bradycardia.⁹¹ It is not known whether progressive alterations in electrocardiographic tracings occur before HF develops.

The chest radiograph may show cardiomegaly caused by the hyperdynamic circulation, signs of congestive HF, and, on occasion, extramedullary hematopoiesis as indicated by the lobulated soft tissue opacities of the ribs anteriorly and posteriorly. N-terminal pro-B-type natriuretic peptide (NT-proBNP) and B-type natriuretic peptide (BNP) are significantly increased in documented LV diastolic dysfunction, whereas NT-proBNP appears to have better predictive value in detecting latent LV diastolic dysfunction.⁹² However, one study showed poor correlation of BNP against low myocardial T2*, which predicts future HF.⁵⁰ One possible explanation for this finding is cardiac endocrinopathy and reduced BNP secretion caused by iron toxicity. More recent data suggest that NT-proBNP levels may be useful,⁹³ and further studies are needed.

3.2 Noninvasive Techniques to Measure Cardiac Function

3.2.1 Echocardiography

A number of factors affect cardiac function measurements by different techniques, and this makes comparisons between techniques and different laboratories difficult.⁹⁴ Echocardiography is a very useful cardiac examination because its application is widespread, safe, economical, and routine in clinical practice;

however, image acquisition depends on the operator and the availability of good acoustic windows. Reproducibility is reasonable in normal ventricles, but the quantification of volumes and mass relies on geometric assumptions that do not apply in ventricles undergoing asymmetrical cardiac remodeling, such as in cardiomyopathy,⁹⁵ and measurements show significant interobserver variability. In a small study of 36 patients, a resting LVEF <60% by echocardiography correlated with increased cardiac mortality over a 12-year period.⁹⁶ Echocardiography provides less accurate quantification than CMR, and accuracy decreases with worsening LV function as geometric assumptions lose validity. In addition, typical echocardiography measurements include the papillary muscles in the blood pool, which leads to systematic overestimation of volumes. Echocardiography is the preferred second-line technique after CMR, and 3-dimensional is preferable to 2-dimensional because of improved longitudinal reproducibility. It is important that echocardiography be performed in experienced centers that are used to scanning TM patients in large numbers. Echocardiography is the easiest way to evaluate the diastolic LV function/dysfunction in patients with TM with published guidelines.⁹⁷

3.2.2 Radionuclide Ventriculography

Radionuclide ventriculography during exercise is reported as a sensitive technique for detecting preclinical myocardial dysfunction in patients with systemic iron overload.⁹⁸ However, its use is limited in the current era because of concerns about radiation dose in young people, considerable intercenter variation in normal values of ejection fraction related to differences in background radiation—subtraction techniques, and the availability of other techniques such as echocardiography and CMR, which are usually preferred.

3.2.3 Cardiovascular Magnetic Resonance

CMR is also free of ionizing radiation, noninvasive, and highly reliable. In addition, CMR is independent of geometric assumptions for assessment of LV volumes and function and has been shown to be accurate and reproducible. However, it is more expensive than echocardiography, is performed in a claustrophobic environment, and is limited in patients with cardiac devices (although CMR-compatible devices are now available). Despite the special expertise required to perform and interpret CMR, it is considered the “gold standard” today for the measurement of all LV and RV indexes. With the introduction in recent years of the steady-state free precession technique with much improved blood-myocardium contrast, faster acquisition, and improved temporal resolution of the cine images, the image quality is superior to the spoiled gradient echo sequences, which are more of a historical issue at this point. Steady-state free precession end-expiratory breath-hold cines should be acquired in the vertical and horizontal long-axis planes, with subsequent contiguous short-axis cines from the atrioventricular ring to the apex. LV mass should be calculated from the end-diastolic frames after the epicardial and endocardial borders of the LV are delineated and should include the papillary muscles. End-systolic and end-diastolic volumes are best calculated from the LV volume-time curves generated from all frames of all cines, should exclude the papillary muscles, and should

model LV blood pool changes from systolic valve descent. Such rigorously derived CMR cardiac volumes have the benefit of having recognized normalized values for sex, body surface area, and age for both the LV⁹⁹ and the RV.¹⁰⁰ These covariates have substantial impact on the normal ranges. However, many CMR analysis software packages do not have this full modeling capability, and in that case, normal values appropriate to the software should be used. CMR is more reproducible than other techniques over time^{101,102}; therefore, it is preferred for follow-up of patients over time when it is available. Finally, it is important to compare normal values for LV¹⁰³ and RV¹⁰⁴ function with values obtained in nonanemic TM patients to prevent misdiagnosis of abnormality, as detailed below. Such comparisons are now also available for children.^{105,106} A further value of CMR is related to the use of late gadolinium enhancement, which identifies myocardial replacement fibrosis. This can be useful to identify myocarditis and myocardial infarction, which are uncommon differential diagnoses in HF in TM patients.¹⁰⁷ CMR with late gadolinium enhancement should be considered in any patient who has a positive test result for hepatitis C, has abnormal cardiac function in the absence of cardiac iron, or has other known cardiovascular risk factors, such as chronic diabetes mellitus. Diastolic cardiac function is measured in clinical practice by echocardiography, and CMR is not generally used for this assessment despite the fact that it provides absolute peak filling rates from the volume-time curves¹⁰⁸ that are at higher spatial resolution than provided by radionuclide ventriculography. Performance of CMR requires training and experience to obtain results of the required quality, as detailed in guidelines.^{109,110}

3.2.4 Cardiac Computed Tomography and Exercise Testing

There are few data on the use of cardiac computed tomography in TM, but it is a fast technique to assess cardiac function,¹¹¹ and liver attenuation correlates with MR-derived liver iron concentration, but only at moderately to severely increased levels of iron in the liver.¹¹² No significant data exist on measurement of cardiac iron by computed tomography. β -Blockers are generally used as premedication, which can affect the functional analysis, and radiation exposure is significant with repeated use. Exercise stress testing might be considered useful to unmask subclinical LV dysfunction in TM, but in practice, it appears to have limited value. Exercise capability is affected by chronic anemia, the typical small body habitus of TM patients, and other factors.

3.3 T2* CMR Measurement of Cardiac Iron

Myocardial iron deposition can be quantified reproducibly with myocardial T2*,^{5,113–115} a relaxation parameter that arises principally from local magnetic field inhomogeneities that are increased with iron deposition. T2* is the time taken for decay of the myocardial signal by 63% and is measured in milliseconds. T2* is related to T2 by summation of tissue relaxation (T2) and magnetic inhomogeneity, known as T2 prime (T2'), in the form $1/T2^* = 1/T2 + 1/T2'$. In clinical medicine, it is usual to use these decay times to assess magnetic relaxation, but basic science-based investigations typically use

the rate of relaxation (R), and this relation can be rewritten as $R2^* = R2 + R2'$, with the units of measurement being inverse seconds (s^{-1}).

As myocardial stores increase in the heart, ferritin breakdown increases into particulate hemosiderin, which is a form of ferrihydrite (hydrated iron oxide). The hemosiderin to ferritin ratio is significantly higher in cardiac siderosis than in normal hearts.¹¹⁶ This disrupts the local magnetic field homogeneity, causing reduced T2* values in inverse relation to iron concentration. Iron that is safely stored in ferritin or hemosiderin is nontoxic, yielding hearts with low T2* and normal function; however, high iron stores predispose patients to development of cardiac dysfunction in the future.^{5,38} An improvement in myocardial T2* resulted in improvement in LVEF in observational, prospective, and randomized controlled studies of iron chelation in thalassemia patients.^{8,9} Myocardial iron deposition is also strongly associated with RV dysfunction, which mirrors the decrease in LV function seen with worsening cardiac iron loading and decreasing T2*.¹¹⁷ Further studies are required to determine the relative importance of RV function compared with LV function and establish whether novel treatment strategies targeted to the RV may prove useful.

For measurements of myocardial T2*, imaging of a single short-axis mid-LV slice is performed at multiple separate echo times to measure the signal decay of the myocardium. Gradient-echo T2* CMR is the preferred technique rather than a spin-echo T2 sequence because of its greater sensitivity to iron deposition and lower sensitivity to motion. The first described method required multiple separate image acquisitions, each of which required a breath hold.⁵ This was time consuming and prone to artifacts that made it difficult to assess the exact myocardial borders with longer echo times, and it created problems with image registration between the images. A multiecho sequence is now standard, because this allows the acquisition of a single short-axis midventricular slice at multiple echo times in a single breath hold.¹¹⁸ This also has the advantage of T1 independence because of the constant repetition time between all echo times in contrast to the lengthening repetition time with increasing echo time in the multiple breath-hold T2* measuring sequence. A gating delay of 0 ms after the R wave is chosen to obtain myocardial images in a consistent position in the cardiac cycle irrespective of the heart rate. The most recent technical improvement in the T2* sequence has been the development of the black-blood sequence.^{119,120} This sequence greatly reduces blood signal, which significantly reduces the blood artifact propagating in the phase-encoding direction that typically spreads across the interventricular septum. This reduces measurement variability. A reproducible multislice T2* sequence has been reported,¹²¹ but no clinical advantage of this more complex protocol has been demonstrated. In particular, the T2* and iron concentration in the septum have been shown to be highly representative of mean total cardiac iron concentration,^{7,122,123} and the variation in iron between ventricular myocardial segments appears clinically insignificant.⁷

For analysis of the images, software that is clinically validated for this application should be used. Such software incorporates safeguards against incorrect handling and

interpretation of the data, which can have clinical implications.¹²⁴ A full-thickness region of interest is measured in the LV myocardium that encompasses both epicardial and endocardial borders. This is best located in the interventricular septum and distant from the superior and inferior cardiac veins, which can cause susceptibility artifacts and falsely lower the T2* measurement.

Currently, all T2* MR measurements have been validated at a field strength of 1.5 T. Although 3T scanners are now commonly installed, there is very little clinical experience of their use in TM. T2* values at 3T are shorter than at 1.5 T,^{125,126} and the potential for artifacts is greater. In view of the importance of the measurement of myocardial T2* and the very limited clinical experience at 3T, we recommend that all clinical T2* MR be performed at 1.5 T.

3.4 Normal Ranges in TM

In healthy, nonanemic subjects, LV and RV volumes and function (systolic and diastolic) vary with sex, age, and body surface area. Identification of early abnormality requires rigorous analysis and appropriate reference ranges that normalize for all 3 variables. These ranges are available in both tabular and graphic form for analysis, including papillary muscles as myocardium and modeling for systolic valve descent, and are of significant clinical and research utility for the correct and accurate interpretation of CMR studies.^{99,100} Values for young patients are also available.^{105,106}

In TM patients without cardiac iron overload, LV end-diastolic volume is increased and LV end-systolic volume is decreased, which leads to increased LV stroke volume, LVEF, and cardiac output compared with healthy control subjects after normalization for body surface area.¹⁰³ The hyperdynamic circulation also leads to an increased LV mass. The same is true for the RV indexes: RV stroke volume and cardiac output are higher, and RV ejection fraction is also higher, mostly secondary to increased RV end-diastolic volume compared with healthy, nonanemic control subjects.¹⁰⁴ The observed differences in LV indexes seen in TM patients without iron overload are more pronounced than the RV indexes compared with healthy, nonanemic control subjects. It is important to use the “normal for TM” ranges for TM patients, because this may enhance diagnostic accuracy for detection of cardiomyopathy.

4. Treatment of TM: The Iron Chelators

4.1 Basic Chelation Principles

Iron has 6 electrochemical coordination sites that need to be tightly bound by an iron chelator to block the ability of the iron ions to catalyze redox reactions and to allow efficient transport and excretion without iron redistribution. Iron chelators should reduce tissue iron levels, prevent excessive organ iron accumulation, and neutralize toxic labile iron pools. Based on the number of the coordination sites, iron ligands are termed hexadentate, tridentate, and bidentate. Denticity is directly related to the molecular weight: Hexadentate chelators have a higher molecular weight than tridentate and bidentate molecules. However, diffusion through biological membranes and

hence absorption from the gastrointestinal tract and cellular penetration are governed not only by molecular size but also by lipophilicity and net molecular charge.¹²⁷ Selectivity and affinity for the ferric (Fe)³⁺ oxidation state are important characteristics of an iron chelator. These properties reduce the chelation of other biologically important bivalent metals, such as copper and zinc, whereas the effect on nonessential trivalent cations, such as aluminum and gallium, remains negligible. Under biological conditions, the affinity of chelators for iron and the stability of ligand-metal complexes is expressed as pF³⁺ value, that is, the negative logarithm of the concentration of the free Fe,³⁺ measured in a solution of 10 μ mol/L ligand and 1 μ mol/L Fe³⁺ at pH 7.4. The larger the pF³⁺, the higher the stability of the ligand-metal complex. There are 3 commercially available iron chelators, each with very different properties (Table 2).

4.2 Deferoxamine

Deferoxamine was the first approved iron chelator to be introduced into clinical use in the 1960s. It is a hexadentate ligand that binds to iron in a 1:1 molar ratio. Deferoxamine is not absorbed effectively by the gastrointestinal tract and must be administered parenterally. Its plasma half-life is very short at \approx 20 minutes¹²⁸; therefore, the drug is usually given as a 10% solution subcutaneously by use of a small portable pump. When intensive chelation is needed, deferoxamine can be given as a continuous intravenous infusion. Parenteral administration of deferoxamine is cumbersome, which can adversely affect adherence to treatment. The most common deferoxamine side effects are local infusion-site reactions (induration, erythema, swelling, and itch). Serious adverse events have occurred, particularly in patients taking higher deferoxamine doses relative to their iron burden.^{129,130} Ophthalmologic and audiological tests and growth monitoring are recommended. *Yersinia* and *Klebsiella* infections have been reported in patients treated with deferoxamine.^{131,132} Renal toxicity and acute respiratory distress syndrome, particularly after excessively high intravenous doses, have been described.¹³³

4.3 Deferiprone

Deferiprone is a bidentate ligand that binds to iron in a 3:1 molar ratio.¹³⁴ Deferiprone is absorbed rapidly from the upper gastrointestinal tract, and the peak serum concentration occurs 45 to 60 minutes after oral ingestion in fasted patients and up to 2 hours in fed patients.¹³⁵ Deferiprone is mainly metabolized to a glucuronide conjugate that lacks iron-binding capability. Given its relatively short plasma half-life of 1.5 to 2.5 hours, the drug is usually administered 3 times daily. Free deferiprone, glucuronide metabolite, and the iron-deferiprone complex are mainly excreted renally.¹³⁵ The drug is available as tablets or as oral solution. The most common adverse reactions associated with deferiprone are gastrointestinal symptoms (nausea, vomiting, abdominal pain) and a transient increase of liver enzymes.¹³⁴ Arthropathy may occur, ranging from mild pain in 1 or more joints (usually knee) to severe arthritis, and low plasma zinc levels have been reported in a minority of patients. Agranulocytosis (absolute neutrophil count $<0.5 \times 10^9/L$), the most serious adverse

Table 2. Main Features of the Iron Chelators

Drug	FDA Approved	EU Approved	Route	Typical Chronic Dosing, mg·kg ⁻¹ ·d ⁻¹	Frequency	Excretion	Main Adverse Effects
Deferoxamine	Yes	Yes	SC (IV in heart failure)	20–50	8- to 14-h infusion for 5–7 d/wk	60% Urine; 40% feces	Sensorineural deafness, visual disturbance, skeletal abnormality, growth retardation
Deferiprone	Yes	Yes	Oral	75–100	×3/d	75%–90% Urine	Agranulocytosis, GI disturbance, arthropathy
Deferasirox	Yes	Yes	Oral	20–40	×1/d	≈90% Feces	Rash, GI disturbance, rise in creatinine

EU indicates European Union; FDA, US Food and Drug Administration (United States); GI, gastrointestinal; IV, intravenous; and SC, subcutaneous.

reaction with deferiprone, has been reported in ≈1% of treated patients (0.6 cases per 100 patient-years of treatment). A less severe form of neutropenia (absolute neutrophil count $0.5\text{--}1.5 \times 10^9/\text{L}$) has been reported in ≈5% of patients treated with deferiprone, particularly nonsplenectomized patients and in association with viral infections.¹³⁴ The neutrophil count should therefore be monitored every week to detect early signs of agranulocytosis. Temporary discontinuation or dose adjustment may be beneficial for the common adverse events, whereas in the case of agranulocytosis or neutropenia, the drug should be stopped immediately, and patients should contact their physician. Patients should also be advised to report immediately to their physician any symptoms indicative of infection, such as fever, sore throat, and flulike symptoms.

4.4 Deferasirox

Deferasirox is an orally active tridentate chelator that binds iron in a 2:1 molar ratio. Single oral doses of deferasirox are absorbed rapidly, achieving peak plasma levels within 1 to 3 hours after administration; with a mean elimination half-life of 8 to 16 hours, plasma levels are maintained within a therapeutic range over 24 hours, which supports once-daily administration.¹³⁶ Feces are the main route of excretion.¹³⁷ Deferasirox is available as orally dispersible tablets that are dissolved in water or juice and given at least 30 minutes before a meal. Deferasirox has a clinically manageable safety profile with appropriate patient monitoring. The most common adverse events are mild to moderate transient gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal pain), diffuse maculopapular skin rash, and increased alanine aminotransferase and serum creatinine levels.¹³⁶ Such events rarely require discontinuation of treatment but are frequently resolved either spontaneously or after dose interruption/adjustment. Safety data on long-term usage accord with short-term data.¹³⁸ Mild elevations in serum creatinine levels occur in ≈33% of patients, but few experience elevations beyond the normal range.¹³⁹ Although the changes in serum creatinine are usually nonprogressive, deferasirox is currently contraindicated in patients with creatinine clearance <40 mL/min or serum creatinine greater than twice the age-appropriate normal threshold.¹⁴⁰ Several cases of Fanconi syndrome have been reported with deferasirox.¹⁴⁰ In some cases, overdose related to low total iron burden has been reported. Cases were

reversible with cessation of the drug. Auditory and ocular toxicities occur in ≈1% of patients treated with deferasirox. Patient monitoring, including tests of renal and hepatic function, is recommended for all patients receiving deferasirox.

5. Diagnosis of HF in TM

5.1 Diagnosis of HF With Impaired Ventricular Function in Nonanemic Subjects

HF can be defined as an abnormality of cardiac structure or function that leads to failure of the heart to deliver oxygen at a rate commensurate with the requirements of the metabolizing tissues, despite normal filling pressures (or only at the expense of increased filling pressures).¹⁴¹ For the purposes of these guidelines, HF is defined clinically as a syndrome in which patients have typical symptoms (eg, breathlessness, ankle swelling, and fatigue) and signs (eg, elevated jugular venous pressure, pulmonary crackles, and displaced apex beat) resulting from an abnormality of cardiac structure or function.

5.2 Diagnosis of HF in TM

Many symptoms typically present in HF are common in anemia, which can make the diagnosis of HF difficult to make on clinical grounds alone. More reliable clinical markers for the development of HF are changes in symptoms, such as increased exertional dyspnea. Additional symptoms that are prevalent in the TM population relate to liver congestion (abdominal or back pain and nausea) and dizziness/presyncope (arrhythmias).¹⁴² Other symptoms include failure to tolerate standard transfusions. Orthopnea and peripheral edema are late symptoms. The absence of the clinical features of HF (such as hepatomegaly, peripheral edema, raised jugular venous pressure, and lung crackles) does not exclude severe cardiac impairment. The classic signs of HF may appear late, and this has the potential to delay diagnosis and appropriate intensification of chelation.¹⁴² As in conventional HF, blood tests are frequently abnormal. Liver function tests and serum ferritin may be raised because of congestion. An elevated BNP is expected but is a late sign.⁵⁰

6. Prediction of HF in TM

The association between biomarkers and HF can be studied through cross-sectional studies that show the contemporaneous

relation of the biomarker to HF, although this approach ignores previous levels of the biomarker, or by longitudinal studies that relate a biomarker to future outcome in a prospective fashion either with single or serial measurements. The latter study design has significant advantages but is harder to execute.

6.1 Ferritin

Trends in ferritin level are useful in monitoring the direction of body iron loading but may not predict cardiac iron loading. Long-term elevations in ferritin predict cardiac mortality. Studies suggest that a ferritin level $>2500 \mu\text{g/L}$ indicates a raised risk,^{28,42,143} but there is no threshold effect, and risk is increased even down to ferritin levels of $1000 \mu\text{g/L}$. A low ferritin level does not guarantee freedom from HF. Single cross-sectional ferritin measurements may be misleading because they may not reflect long-term ferritin levels and do not correlate with cardiac iron levels.⁵ Ferritin levels may also be increased by inflammation or infection (especially in hepatitis C, which is highly prevalent worldwide in adult TM) and may be decreased by vitamin C deficiency. Therefore, in individual patients, the serum ferritin level may not reflect the individual total body iron load and cardiac risk.^{5,96,143}

6.2 Liver Iron

The relation between liver iron and cardiac iron is complex. Single cross-sectional liver iron measurements in patients on long-term iron chelation may be misleading because they may not reflect long-term liver iron levels and do not correlate with cardiac iron levels.⁵ It is likely that failure to control liver iron over the long term increases the risk of cardiac iron loading.^{143,144} Levels of liver iron >15 to $20 \text{ mg/g Fe dry weight}$ are associated with liver damage, liver fibrosis, and the presence of increasing levels of free plasma labile iron and free chelatable iron.¹⁴⁵ It has been shown that noncompliance with iron chelation treatment is a major predictive factor for cardiac iron loading in patients with high ferritin levels, which implies high liver iron loading.¹⁴⁶ However, high levels of free plasma labile iron may be the actual source of iron that loads into the heart.¹⁴⁷ Therefore, high liver iron levels per se may not be the best way to view the cardiac risk associated with liver iron loading. Long-term excessive liver iron loading with poor current compliance with iron chelation therapy may be the worst combination of factors for cardiac iron loading. Thus, although control of liver iron over time is likely to be important in prevention of cardiac iron accumulation, single or even repeated measurements showing low liver iron do not guarantee protection from cardiac disease.¹⁴⁸

6.3 Cardiac Iron ($T2^*$)

Cardiac $T2^*$ has been calibrated to cardiac iron in animals and humans.^{7,123,149} The lower limit of normal is 20 ms ,⁵ a threshold below which myocardial $T2^*$ in normal subjects does not occur. However, this is recognized as a conservative threshold, because $T2^*$ calibration data suggest 20 ms equates to $1.1 \text{ mg/g iron dry weight}$, which is approximately twice the historically reported normal mean level of human myocardial iron.¹⁵⁰ The probability of a reduced ejection fraction increases as cardiac iron increases (cardiac $T2^*$ falls).^{5,38,43}

The longitudinal follow-up of patients has shown that cardiac $T2^* < 10 \text{ ms}$ predicts HF. Of patients who developed HF, 98% had a cardiac $T2^* < 10 \text{ ms}$. Patients with a cardiac $T2^* < 6 \text{ ms}$ have a 50% likelihood of developing HF within 12 months if no change in iron chelation treatment is instituted.⁶ A 3-tier risk model was established on the basis of this finding (low risk, $>20 \text{ ms}$; intermediate risk, $10\text{--}20 \text{ ms}$; and high risk, $<10 \text{ ms}$). A normal cardiac $T2^*$ has a very high predictive value for exclusion of HF for 12 months.³⁵

6.4 LV Ejection Fraction

An increased risk of clinical HF has been demonstrated for patients with falling LVEF or absolute values below the lower limit of the normal range^{96,151}; however, there are problems with the use of LVEF. Reproducible measurements of LVEF require excellent attention to detail in acquisition and analysis. CMR has superior reproducibility compared with echocardiography for measurement of LVEF.^{101,102} In addition, the absolute level of LVEF varies between imaging techniques and between centers. Finally, changes in LVEF are a late event compared with the early warning of cardiac loading seen with intermediate levels of cardiac $T2^*$ ($10\text{--}20 \text{ ms}$). This occurs because as iron accumulates in the heart, the early decrement in LVEF may be modest and within the normal range until iron storage capacity is exhausted. The relation between the measured $T2^*$ and LVEF is therefore shallow until a critical level is reached, after which rapid deterioration may occur. Therefore, the $T2^*$ technique can identify those patients who may benefit from earlier chelation therapy to avoid overt HF, which can be difficult to reverse. Because $T2^*$ measures storage iron in the form of hemosiderin, and acute toxicity is related to free iron, LVEF can improve faster than the cardiac $T2^*$ with acute chelation treatment, which can drive the free iron to zero despite the presence of high tissue levels of hemosiderin. Alternative measures of systolic LV function such as tagging and myocardial phase mapping may be more sensitive to myocardial $T2^*$, but further experience is needed to evaluate their possible clinical role.¹⁵²

6.5 Diastolic Function and Compliance

There are few data relating diastolic function to outcome. In one report of 45 patients with 15 years of follow-up, 11 patients died, and restrictive LV filling was predictive of death.¹⁵³

6.6 Relative Predictive Power

Direct comparison of cardiac $T2^*$ against cross-sectional measurements of liver iron and serum ferritin shows that cardiac $T2^*$ is the most significant predictor of the development of HF.⁶ There is no direct comparison of cardiac $T2^*$ and LVEF for prediction of HF. In the presence of low $T2^*$, the imperative for aggressive cardiac chelation, antifailure therapy, and hospitalization is increased if the LVEF is reduced or falling on closely repeated measurements.

6.7 Age

In children who have received regular transfusions and iron chelation, cardiac loading before the age of 10 years is

uncommon.⁵⁴ Cardiac iron loading in younger children has been seen in patients receiving little or no iron chelation treatment.⁵⁵

6.8 Exercise Capacity

There are contradictory reports regarding exercise capacity in TM patients compared with healthy subjects. TM patients have been reported to have limited exercise capacity,¹⁵⁴ with increasing cardiac iron correlated with decreasing exercise capacity.¹⁵⁵ Others have found normal exercise capacity but a decreased ratio between cardiac index and oxygen extraction at peak exercise in TM patients, which shows a lower contribution of the cardiovascular system to maintain oxygen uptake.¹⁵⁶ Another study showed similar or reduced exercise capacity in TM patients, with normal oxygen delivery but reduced utilization.¹⁵⁷ Consensus opinion is that exercise capacity is often consistent with the degree of anemia and does not appear to be useful to diagnose preclinical disease.¹⁵⁸

7. Conventional Medical Treatment of HF

The medical management of chronic HF without hemoglobinopathy is based on published guidelines.^{159–164} In general, the recommendations are similar among guidelines. Overall, management of TM with chronic HF and cardiomyopathy should follow these guidelines unless specified in the following sections.

8. Why Treatment of HF in TM Is Different

8.1 Introduction

Although the main aspects of the diagnosis and management of HF are well known, the acute and chronic care of HF that complicates TM differ in a number of important ways. First, the age of the population being treated is much younger.¹⁶⁵ Second, it is a toxic cardiomyopathy related to myocardial iron accumulation, so that there is the important prospect of complete resolution of ventricular dysfunction with treatments directed at iron removal rather than directly at myocardial performance. Third, there may be important comorbidities that require recognition and specific treatment in their own right.

8.2 Reversibility

Iron cardiomyopathy is the most common and feared complication of TM, but because it is caused by iron toxicity, it is reversible.

8.3 Endocrine, Metabolic, and Infectious Comorbidities

TM patients with cardiac iron overload also have iron overload in many endocrine glands,^{166,167} including the pancreas, pituitary, thyroid, parathyroid, and adrenal gland. The endocrine and metabolic deficiencies can mimic or exacerbate HF. Primary myocardial dysfunction can be caused by hypoparathyroidism^{168–170} and hypothyroidism,^{171,172} and these conditions may exacerbate iron cardiomyopathy. Decreased adrenal reserve is also common in TM,^{173–178} and patients in HF should be treated as though they have adrenal insufficiency until

proven otherwise. Hypogonadotrophic hypogonadism is the most common endocrinopathy observed in TM,^{1,179} and low sex steroids may exacerbate HF symptoms.^{180,181} Growth hormone deficiency must also be considered and may contribute to HF. Many TM patients have diabetes mellitus, and insulin resistance and type 2 diabetes mellitus are strongly associated with cardiac iron deposition. Cardiac metabolism is altered, and a propensity to cardiac dysfunction is associated with chronic hyperglycemia and insulin resistance, in which there occurs a shift of cardiac metabolism from glucose to fatty acid oxidation, with associated lipotoxicity, activation of the renin-angiotensin-aldosterone axis, hypertrophy, altered calcium homeostasis, fibrosis, and microvascular disease.¹⁸² Thus, the phenotype of iron-overload cardiomyopathy may have some overlap with the cardiovascular changes typically associated with type 2 diabetes mellitus. Glucose control must be considered in acute and chronic HF management, ideally by the use of insulin infusions, with meticulous avoidance of hypoglycemia and hyperglycemia.

The chronic anemia and ineffective erythropoiesis of thalassemia are associated with a hypermetabolic state that leads to deficiencies in a number of metabolically important cofactors such as thiamine, B6, and folate.¹⁸³ Fat-soluble vitamins are decreased,^{184–186} as are trace elements such as zinc, copper, and selenium.^{183,185,187} Carnitine deficiency is also common, and carnitine replacement therapy has been associated with clinical improvement in uncontrolled studies.^{188,189} Hence, in any TM patient presenting with decreased cardiac function, it is prudent to eliminate possible contributions from thiamine, carnitine, or extreme vitamin D deficiencies (25 hydroxyvitamin D levels <10 ng/dL),^{190–192} given the benign nature of replacement therapy.

Sepsis is the second-leading cause of death in TM patients and may precipitate HF. Whether sepsis disrupts iron stores in the heart or whether the hemodynamic stress induced by sepsis merely unmasks compensated HF is unknown. Many older TM patients have been subjected to splenectomy and are therefore vulnerable to severe infection by encapsulated organisms¹⁹³; in patients treated with the chelator deferoxamine, increased iron stores may also predispose to bacterial infection, particularly with some unusual pathogens, including *Yersinia enterocolitica*.¹³¹ Chronic antigen exposure with blood transfusion also downregulates cell-mediated immunity and may leave TM patients at risk for fulminant infections.^{194–197}

Myocarditis prevalence in 1995 was estimated to be 4% among a cohort of Greek TM patients, and it was suggested that such infections were the cause of LV failure.¹⁹⁸ The same group hypothesized an association of the major histocompatibility subtypes HLA-DRB1*1401 and HLA-DQA1*0501 with LV HF.¹⁹⁹ Since these reports were published, improved access to iron chelation appears to have decreased the incidence of myopericarditis significantly.^{5,200,201} The clinical presentations of myocarditis and decompensated HF attributable to severe iron overload have considerable overlap, except that iron-induced cardiomyopathy does not typically manifest with chest pain, diffuse ST-T-wave changes, or increased cardiac enzyme levels. Given the overlap and the possibility that iron may exacerbate myopericarditis, all TM patients with acute reductions in cardiac function should receive intensified iron

chelation therapy empirically until cardiac iron loading can be confirmed by CMR.

8.4 Different Baseline Hemodynamics and Different Response to Loading

Patients with TM have an increased cardiac index as a consequence of their chronic anemia.^{53,103,200} The heart rate and stroke volume may both be elevated compared with age- and sex-matched control subjects. Thus, mild tachycardia and cardiomegaly must be viewed as physiological compensation for the anemia rather than pathological associations that imply myocardial iron overload. The hyperdynamic circulation characteristic of this group accounts in part for the increased reference ranges for ventricular ejection fractions in thalassemia.¹⁰³ Despite having an increased cardiac index, TM patients also have lower systolic blood pressure and a blunted temporal variability of blood pressure, consistent with a markedly decreased systemic vascular resistance.^{75,202} Despite having lower blood pressure and higher cardiac index, measurements of aortic and peripheral vascular compliance reveal decreased values in TM patients that worsen with iron overload and with age.^{82,83,203–205} Iron overload exacerbates oxidative stress in the vasculature, accelerating age-related increases in vascular stiffness.²⁰⁵ Flow-mediated dilation, a marker of endothelial function, is proportional to cardiac T2*, which suggests commonality between cardiac and vascular iron overload.⁹ Chelation therapy for 1 year improves endothelial function, which suggests that the relationships are causal rather than correlative.^{9,83} Increased systemic vascular elastance creates a ventricular-vascular mismatch in TM patients that can lead to unfavorable ventricular remodeling and increased cardiac oxygen consumption.^{206,207}

The aforementioned physiological differences affect the success of HF treatment in thalassemia. Baseline preload is high because of chronic anemia. Therefore, although diuresis can lower wall stress and improve symptoms attributable to fluid overload, overdiuresis can precipitate acute renal failure by excessive reduction of preload, especially in the setting of compromised oncotic status with chronic liver disease (iron induced, hepatitis C) and hypoalbuminemia.¹⁸ Older patients may have a restrictive physiology that does not tolerate either overfilling or underfilling. Although there are no clear data, maintaining higher hemoglobin levels in patients with HF may be beneficial. Afterload reduction is often the mainstay of conventional acute HF treatment and can improve ventricular-vascular coupling in dilated cardiomyopathy. Unfortunately, chronic anemia results in low systemic afterload, and additional poor vascular compliance in the TM patient may limit the afterload reduction that is tolerated (even relatively young patients may have stiff vessels). Afterload reduction should be titrated very carefully against urine output and clinical response rather than target pressures, which are often derived from experience in non-TM populations and not applicable in this hemodynamically unusual group of patients. Overall, there are no data on the use of conventional HF treatments in TM patients with HF, but it is inadvisable to withhold such treatments that have been shown to have significant mortality and morbidity benefits in patients without thalassemia. However, exceptional caution is required in the setting of acute decompensated HF, and this is discussed further in the next section.

Although positive inotropes are often used to improve ventricular-vascular coupling, their use comes with significant penalties in iron cardiomyopathy. Most inotropes increase intramyocyte calcium levels, may worsen oxidative stress, and increase electrical automaticity, which may act synergistically with iron-mediated toxicity to the detriment of myocyte function. Thus, we recommend that inotropes should be used with great caution and reserved for desperate situations and that doses should be minimized whenever possible.

8.5 Unique Electrophysiology

Arrhythmias in TM are a mixture of triggered and reentrant arrhythmias.²⁰⁸ Chronic volume overload creates an anatomic substrate suitable for atrial and ventricular reentrant tachycardias and fibrillation by lengthening the conduction paths and increasing dispersion of repolarization. However, patients with thalassemia intermedia, who have larger chamber volumes but little cardiac iron, have fewer cardiac arrhythmias than TM patients, which implies a critical role for iron toxicity.^{200,209} Atrial iron cannot be measured by CMR, but atrial arrhythmia risk correlates with ventricular T2* estimates.⁶ Iron deposition is most common in working muscle and tends to spare the conduction system.^{72,210} Postulated mechanisms for the electrophysiological effects include inhibition of fast inward sodium currents, blockage of ryanodine calcium release channel, and oxidative stress-mediated changes in sarcoplasmic calcium release and reuptake.^{71,211–213}

Clinically, intra-atrial reentrant tachycardia and AF are the most common serious rhythm disturbances.²¹⁴ Ectopic atrial tachycardia and chaotic atrial rhythm may also be seen, particularly in the presence of significant cardiac iron loading.^{27,44} Amiodarone is often successful in controlling atrial arrhythmias and can be a powerful temporizing measure during intensive iron chelation. Long-term therapy may be complicated by hypothyroidism because of iron-mediated thyroid damage²¹⁵; however, amiodarone therapy can often be terminated successfully after 6 to 12 months. Ablation should be reserved for patients who have undergone successful removal of cardiac iron (documented by CMR). Ventricular arrhythmias are more specific for iron cardiotoxicity.²¹⁴ Frequent premature ventricular contractions, by themselves, are not specific for iron cardiomyopathy, but couplets, nonsustained ventricular tachycardia, or mixtures of frequent atrial and ventricular premature contractions should raise clinical suspicion. Historically, sudden death accounts for $\approx 5\%$ of cardiac deaths in TM and is associated with severe iron overload and increased QT dispersion, which suggests iron-mediated repolarization abnormalities and torsade de pointes as a causative mechanism.^{46,216} Ventricular late potentials have also been described in thalassemia and are correlated with serum ferritin levels.²¹⁷ Treatment of potentially life-threatening ventricular arrhythmias in patients with severe cardiac iron burdens is problematic, because the physiological substrate is potentially reversible, and device therapy should be avoided if possible because it precludes further monitoring of cardiac iron stores by CMR. A defibrillation vest may represent a viable therapeutic bridge during intensive iron chelation therapy.

9. Treatment of Acute Decompensated HF With Reduced Ejection Fraction

9.1 Recognition of Acute HF

Acute decompensated HF is recognized as a clinical syndrome that includes progressive dyspnea and significant fluid retention. A significant presenting feature in TM can be abdominal (or other location) pain from distended organs such as the liver. This is usually associated with reduced ventricular function and raised BNP.

9.2 Mortality Rate in Acute HF

The death rate attributable to HF in historical series was 50% within 1 year.^{27,44} In 52 patients with mean LVEF of 36%, there was 48% survival after 5 years with no change in iron chelator and use of cardiac medications.⁴⁶ In recent years, with the introduction of continuous intravenous deferoxamine treatment, survival has improved, with a report of this treatment showing survival of 6 of 7 patients.⁴⁷ Deferoxamine intensification (continuous intravenous or subcutaneous) showed survival in 17 of 20 patients.²¹⁸

9.3 Where Should Patients With HF Be Treated?

This is a medical emergency and requires specialized medical care. Delay in starting appropriate chelation therapy can be life-threatening. On presentation, advice should be sought about treatment from a specialist center that is experienced in treatment of HF in thalassemia patients. Such a center is expected to have a larger volume of TM patients under care and have experience with less common complications. Early transfer of the patient to the specialist center is strongly advised where possible to allow integrated cardiologic and hematologic care with doctors skilled in handling HF in TM. There are some data supporting this approach to improve cardiac outcomes.^{219,220} When admission to a specialist center is not possible, close liaison with such a center is mandatory.

9.4 Management of Acute Decompensated HF in TM

The aim of treatment in acute HF is to keep the patient alive so that iron chelator treatment can detoxify the cardiac iron. We recommend the following management strategy:

1. Immediate commencement of 24-hour-per-day continuous (uninterrupted) intravenous iron chelation treatment with deferoxamine 50 mg·kg⁻¹·d⁻¹.^{47–49,151}
2. The patient should have continuous electrocardiographic and hemodynamic monitoring.
3. As soon as is practical, perform bedside echocardiography to confirm the diagnosis of HF and exclude other cardiovascular conditions, including pulmonary embolism.
4. Introduce deferiprone as soon as possible at a dose of 75 mg·kg⁻¹·d⁻¹ (the total dose given in 3 divided doses).^{50,221–226}
5. Supportive hemodynamic therapy should be geared to maintain cerebral and renal perfusion, avoiding aggressive inotropic therapy, which can be detrimental. Blood pressure is typically low in TM patients and should not attract specific therapy if renal and cerebral perfusion is maintained.

6. Only minimum diuretic treatment should be used because of the importance of maintaining preload. Consideration should be given to the alternative maneuver of venous ultrafiltration to remove excess fluid as a means to prevent reduction in preload.^{227,228} but recent results have shown more renal failure and adverse events with its use in non-TM patients with decompensated HF,²²⁹ and further trials are needed to establish its role.
7. Cardiac arrhythmias are common and often respond to continuous iron chelation treatment. Meticulous attention should be given to normalization of electrolyte abnormalities, and consideration should be given to the use of magnesium infusion to stabilize ventricular arrhythmia. Nevertheless, amiodarone is the drug of choice to treat hemodynamically significant arrhythmias. β -Blockers can be used if the hemodynamic status allows. There is no published evidence for the use of these interventions.
8. Maintain meticulous glucose control with insulin/potassium infusion. This may also help with cardiac inotropic status.²³⁰
9. Give hydrocortisone on the presumption of inadequate adrenal response to stress.¹⁷⁵
10. Check thyroid, liver, and renal function and calcium, magnesium, vitamin D, carnitine, and other metabolic parameters and correct these when necessary.
11. Maintain hemoglobin between 10 and 12 g/dL. This may require frequent small-volume transfusions.
12. Search for precipitating conditions such as infections.
13. There is no evidence to support the initiation of angiotensin-converting enzyme inhibitors or angiotensin 2 receptor blockers to manage acute decompensation, and the successful introduction of these drugs is often compromised by poor tolerance caused by low blood pressure. The introduction of β -blockers as an antifailure treatment has the merit of reducing the propensity to arrhythmia and may take priority over angiotensin-converting enzyme inhibitors/angiotensin 2 receptor blockers. The introduction of these drugs can be considered for management of chronic HF, after the patient is stabilized and is past the acute decompensation period.
14. Cardiac T2* should be performed as soon as is practical. If cardiac T2* is >20 ms, then myocarditis should be considered as a cause of HF, using a standard CMR myocarditis protocol.²³¹

9.5 Additional Notes

1. Clinical stabilization can occur within 14 days after commencement of continuous iron chelation treatment but can also take months.
2. Patients with renal failure may require early dialysis to remove the iron chelator and, although experience with this is limited, efficacy is not proven and may vary by chelator.
3. Deferasirox has not been evaluated in acute HF and may be ill-advised in the presence of marginal renal perfusion.
4. Consideration should be given to mechanical support devices to support both ventricles, bearing in mind the RV is often compromised. There is no published evidence for this approach.

5. Cardiac transplantation has been used, but its relevance is questionable in the modern chelation era.^{232–235}
6. Cardiac storage iron is removed very slowly from the heart, even with intensive iron chelation. Treatment will need to be continued for several years and should be monitored by regular T2* and cardiac function assessments. Iron chelation treatment may require adjustment according to liver iron and serum ferritin levels to prevent chelator-mediated toxicity.
7. Compliance with iron chelation treatment is essential for long-term survival of acute cardiac failure, but long-term follow-up by a specialist center is essential to achieve optimal outcomes.^{219,220}
8. Long-term intravenous deferoxamine treatment requires careful management of the intravenous line, anticoagulation, and scrupulous sterile access techniques. Careful consideration of the risk and benefits of this approach must be given on a case-by-case basis.
9. Conversion from 24 hours/day intravenous to 24 hours/day subcutaneous deferoxamine iron chelation treatment can be considered after the acute period.¹⁵¹
10. Combination therapy with daily subcutaneous deferoxamine and daily oral deferiprone (for the avoidance of doubt, both drugs are taken together every day) has been used extensively for long-term management of patients with impaired LV function without decompensated HF.⁵⁰ The use of subcutaneous deferoxamine infusion avoids the infection risk of long-term intravenous infusion.
11. After resolution of decompensated HF, treatment may need to continue for several years to remove cardiac iron in thalassemia.⁴⁷ In hemochromatosis, cardiac iron has been shown to persist even when venesection has resulted in hypoferremia and iron deficiency anemia.²³⁶
12. Treatment should be monitored by assessing clinical status, LVEF (which can improve substantially within weeks), cardiac T2* (which improves over months), and ferritin trend.

10. Treatment of Myocardial Iron Overload Without Cardiac Decompensation

10.1 Level of Urgency

Many factors come into play when considering whether to escalate therapy in response to detection of cardiac iron (T2* <20 ms) in an asymptomatic patient with normal or near-normal LVEF. These include the severity of cardiac iron loading, whether there is any evidence of preclinical cardiac toxicity, longitudinal trends in cardiac iron, liver iron burden, and patient compliance.

Without escalation in therapy, the prospective risk for developing HF in 1 year is 47% if cardiac T2* is <6 ms, with a relative risk of 270 compared with patients having a T2* >10 ms.⁶ In an observational study of 652 patients followed up for up to 7 years, only 1 of 80 HF episodes occurred in a patient who had a T2* >10 ms.⁶ Because outcomes for symptomatic HF are poor,⁴⁸ many thalassemia centers will treat patients who have T2* <6 ms similar to those with overt HF. Patients having T2* between 6 and 10 ms are often placed on intensified but not necessarily maximal chelation therapy. Patients with T2* between 10 and 20 ms can often be managed more

conservatively, with modifications of chelator dose, efforts to improve patient compliance, or alternative or additional chelators. Preclinical reductions in heart function also warrant escalation in chelation therapy.¹⁵¹ Many patients with mild reductions in heart function are completely asymptomatic but are at significantly increased risk for progression to HF and death.¹⁵¹ CMR estimates of cardiac function can also be collected easily at the time of cardiac T2* assessment. As noted above, the role of other preclinical markers of cardiac iron toxicity, including arrhythmias, QT prolongation, and exercise capacity, in guiding chelation therapy is currently unknown.^{6,155,216}

Longitudinal trends in cardiac T2* values are also important.¹⁴⁸ Cardiac iron clears slowly, with a half-life of \approx 13.5 months (5% per month) during continuous intravenous deferoxamine,⁴⁷ and a third as fast with intermittent deferoxamine therapy.^{8,9} Therefore, normalization of cardiac iron lags improvements in total body iron burden. A patient whose cardiac T2* has improved from 6 to 8 ms in 1 year should clearly be handled differently from one whose cardiac T2* has declined from 10 to 8 ms over the same interval.

Liver iron burden also plays a role in determining how aggressively one should respond to the presence of cardiac iron. The chelatable iron pool increases with total body iron stores,^{145,237,238} although the mechanisms of this phenomenon are not well understood. Chelators such as deferasirox and intermittently dosed deferoxamine primarily interact with intravascular or hepatic labile iron. When hepatic iron stores are high, changes in cardiac iron may be quite modest until the liver iron levels drop below 5 mg/g.^{148,239} Chelators with better intracellular permeability, such as deferiprone, appear to have superior cardiac iron clearance when liver iron is high.^{8,240}

Lastly, knowledge of patient compliance with medication is essential in determining appropriate chelation for any given patient with cardiac iron overload. Compliance is an important predictor of cardiac chelation efficacy,¹⁴⁶ particularly for chelators such as deferoxamine and deferasirox that act primarily as intravascular sinks to clear cardiac iron. Cardiac T2* measures primarily insoluble, inert hemosiderin, which exists in equilibrium with the toxic labile iron pool. If free drug is available around-the-clock to soak up toxic labile iron, increases in cardiac iron deposition or progression to HF may be less likely, regardless of the measured cardiac T2*. However, labile iron rebounds quickly in the absence of iron chelation,^{241,242} so anything short of perfect compliance is likely to place the heart at risk.^{146,243} Because the intensity of labile iron exposure increases with liver iron concentration,^{145,237,238} the cardiac penalty for noncompliance is likely to be worse for higher liver iron stores.^{144,239}

10.2 Cardiac Iron Chelation Strategies

Deferoxamine, deferasirox, and deferiprone all remove cardiac iron if given in adequate doses and if patient compliance is good. However, each medication has advantages and disadvantages, and optimal therapy must be tailored to each patient. There are many excellent reviews on this subject.^{244–246} The following recommendations are specific to patients with detectable, asymptomatic cardiac iron overload.

10.2.1 Deferoxamine Monotherapy

The half-life of deferoxamine is only 30 minutes, and labile iron rebounds (often with an overshoot) within hours of infusions being stopped. When the drug is given in standard, intermittent subcutaneous infusions, it will clear cardiac iron at 1.1% to 2.2% per month.^{8,9} By contrast, continuously administered deferoxamine clears cardiac iron at nearly 5% per month because labile iron is scavenged continuously, leaving a gradient between the heart and intravascular space. Thus, increasing the days and duration of deferoxamine therapy will tend to improve cardiac iron clearance. The primary limitation of this approach is patient discomfort and inconvenience, which leads to poor patient acceptance. Local skin reactions prevent subcutaneous therapy in some subjects, introducing the known risks of chronic intravascular access. Others are unable or unwilling to undergo chelation during the day because of job or social considerations. We recommend a change in chelation treatment in patients with cardiac siderosis if there is poor compliance with deferoxamine.

10.2.2 Deferiprone Monotherapy

Retrospective studies suggest that deferiprone monotherapy offers superior cardiac protection^{240,247,248} and improves survival compared with routine deferoxamine therapy.^{249,250} Improvements in myocardial iron loading in national strategic programs with treatment regimens including deferiprone have also been reported,^{3,14,252} with associated improvements in outcomes.^{3,14,252} These survival data are recognized by the European Medicines Agency.²⁵³ There is only 1 prospective randomized study comparing deferoxamine and deferiprone monotherapy.⁸ Deferiprone given at 92 mg·kg⁻¹·d⁻¹ cleared cardiac iron at a rate of 2.2% per month, nearly double the rate produced by deferoxamine in the same trial. Deferiprone significantly improved LVEF in contrast to no change in LVEF with deferoxamine,⁸ despite statistically insignificant improvements in hepatic iron concentration. Separate analysis showed that deferiprone also improved RV ejection fraction more than deferoxamine.²⁵⁴ We recommend the use of deferiprone monotherapy in patients with cardiac siderosis, and it is also suitable for patients with reduced LVEF or asymptomatic LV dysfunction. Deferiprone combined with deferoxamine (both given daily together) is commonly prescribed in severe cardiac siderosis for maximum effect (Section 10.2.4).

10.2.3 Deferasirox Monotherapy

Publications from 2 open-label, single-arm trials with multiple reports (cardiac substudy of the EPIC trial [Evaluation of Patients' Iron Chelation With Exjade]^{10,255,256} and US04^{239,257} trial) showed that deferasirox monotherapy can be used successfully in patients with detectable cardiac iron and normal cardiac function. Data from a small case series were in accord.²⁵⁸ However, no change in LVEF was seen in these trials. Cardiac iron clearance rates were 1.3% to 1.5% per month, comparable to those published for deferoxamine. Iron clearance rates, however, may be a function of initial hepatic^{238,239,257} or cardiac^{10,255,256} iron burden. The results of a large randomized controlled trial presented late in 2012 showed the efficacy of deferasirox for removal of cardiac iron (mean dose 36.7 mg·kg⁻¹·d⁻¹), with noninferiority of deferasirox compared with deferoxamine, but no change in LVEF

with treatment.²⁵⁹ We recommend that deferasirox is suitable to treat cardiac siderosis, but we do not recommend the use of deferasirox as first-choice treatment for cardiac T2* <6 ms or in patients with reduced LVEF because of the limited data on efficacy available at this time. We recommend caution in the use of deferasirox monotherapy to treat cardiac siderosis in patients with high liver iron loading, in whom high doses (>40 mg·kg⁻¹·d⁻¹) may be needed and cardiac efficacy may be delayed.

10.2.4 Combined Drug Therapies

Deferoxamine and deferiprone have been combined successfully (both drugs taken together every day or most days) to improve cardiac and hepatic iron clearance.^{260,261} There is evidence of a synergistic shuttle effect between deferiprone and deferoxamine in improving iron clearance.^{69,262} Reversal of cardiac siderosis and improvement in LVEF have been shown in several small trials.^{263–265} In one open-label, single-arm trial of patients with depressed LVEF and severe cardiac iron (T2* <8 ms), combined subcutaneous deferoxamine and oral deferiprone 75 mg·kg⁻¹·d⁻¹ for 7 days a week improved cardiac T2* 3.3% per month and normalized LVEF in all individuals with cardiac dysfunction.⁵⁰ In a randomized controlled trial, patients having T2* between 8 and 20 ms received either deferoxamine monotherapy or deferoxamine combined with deferiprone (both given together, with deferoxamine dosed at 5–6 days per week).⁹ Combined therapy increased cardiac T2* 4.2% per month compared with only 2.2% per month for deferoxamine therapy. RV function was also shown to improve significantly more with combination treatment.²⁶⁶ However, the addition of even as little as 2 deferoxamine doses per week to daily deferiprone appears to greatly improve overall iron balance.²⁶⁷ The use of combination therapy has been associated with improved outcomes in severe cardiac iron loading compared with the use of deferoxamine alone.^{226,268} The use of the combination of deferoxamine and deferiprone is widespread, and this combination is used especially in patients with moderate to severe cardiac iron overload or when LVEF is impaired. We recommend its use in these circumstances, and clinical experience suggests that there are no significant toxicity issues for the combination, although safety reports are limited compared with trials of chelator monotherapy.²⁶⁹ The combination of daily deferiprone with daily deferasirox is currently under investigation, but there are currently very few data to support this attractive regimen.²⁷⁰ Deferasirox has also been combined with deferoxamine.²⁷¹

10.2.5 Sequential Drug Therapies

One randomized trial also suggested that alternating deferoxamine and deferiprone therapies (drugs taken sequentially on different days, but not taken on the same day together) provided comparable cardiac protection to deferiprone monotherapy, with improved control of liver iron concentration.²⁷² This therapy represents another option in patients with mild cardiac siderosis.

10.3 Treatment of Patients With Cardiac Siderosis With Abnormal or Falling LVEF

Patients with myocardial iron loading who have reduced LVEF for TM,¹⁰³ or a consistent trend over time with several

measurements toward abnormality, form a subset of patients identifiable clinically as having early HF, which is usually asymptomatic. The measurement technique used to determine cardiac function will vary according to local availability but can include LVEF, cardiac dimensions, or possibly tissue Doppler parameters. If repeated measures of cardiac function are compared, this must be done using a consistent technology (eg, CMR or echocardiography for all measurements, using the same acquisition technique). Such patients require intensification of chelation. This may only require dose adjustment of current treatment or measures to improve compliance. Should these measures prove ineffective within a few months, or should clinical concern exist, a change in iron chelator regimen is required. We recommend the use of deferoxamine with deferiprone in combination in these circumstances.⁵⁰ This approach is consistent with data from randomized controlled trials,^{9,128} as well as an analysis of the decreased risk of developing HF in patients whose LVEF improved with treatment.²⁷³

11. Monitoring Treatment With Respect to the Heart

11.1 Monitoring of Body Iron Load

Regular monitoring is recommended of ferritin (at least every 3 months) and of liver iron concentration by MRI (annually). The trend indicates the direction of body iron loading, which reflects the balance of transfusional iron intake and iron chelator-mediated iron excretion (chelator regimen and patient compliance). There is little useful relation clinically between single measurements of ferritin and cardiac T2* in patients already receiving chelation therapy.⁵ Failure to control ferritin on a long-term basis increases the likelihood of heart disease. Increased cardiac risk has been shown with long-term ferritin >2500 $\mu\text{g/L}$,^{28,143,146,151} as well as for values >1000 $\mu\text{g/L}$.¹ Ferritin as a single measure of total body iron can be misleading, however, and liver iron concentration can be used as an additional measure to provide quantification of total body iron stores²⁷⁴ and hence the risk of progressive liver damage.²⁷⁵ Single estimates of liver iron concentration by T2* do not correlate with cardiac T2* in patients receiving chelation therapy⁵; however, there is a relationship between a single liver iron concentration measurement and cardiac survival.¹⁴³

11.2 Clinical Cardiac Monitoring

Patients receiving regular transfusion and iron chelation should be assessed formally for their cardiac status (history, physical examination, and auscultation) beginning at the age of 10 years and annually thereafter. Ideally, this assessment should be performed by a cardiologist with expertise in iron-related cardiac disease, working closely with clinicians at a reference center. Such an approach, including the cardiac investigations, increases the likelihood of identifying pre-clinical cardiac disease, which permits early intensification of treatment and prevents the development of HF.

11.3 Cardiac Investigations

It is recommended that annual electrocardiography and echocardiography (chamber dimension and function) be performed.

The first CMR for cardiac T2* should be performed as soon as the child can cooperate without sedation or anesthetic, which is typically between the age of 6 and 10 years. After this, annual assessment of T2* CMR is typical, but individual patient factors will determine the frequency of repetition. For example, patients at high risk (T2* <10 ms, reduced LVEF, poor compliance, treatment interruption) may require scanning every 6 months. In the patient with stable chelation and stable cardiac T2* >20 ms, scans can be repeated less frequently (every 2–3 years).

11.4 LVEF Response During Chelation

The trend in LVEF and cardiac dimensions is useful to monitor response to treatment. A worsening in cardiac function is a poor prognostic sign¹⁵¹ and an indication for intensification of treatment. Different responses in the LVEF to iron chelators have been demonstrated in cardiac siderosis without decompensation. Data from control arms of 2 randomized controlled trials showed subcutaneous deferoxamine did not significantly improve LVEF in mild to moderate cardiac iron overload,^{8,9} whereas the active arms of these trials showed significant increases in LVEF with deferiprone,^{8,9} and this has been found in other trials.²⁷⁶ These findings are in accordance with those of cross-sectional studies.^{240,248} LVEF does not increase with deferasirox treatment in cardiac siderosis.^{10,239,255,256} The improvement in LVEF probably reflects relief of subclinical cardiotoxicity; it is associated with a lower risk of developing HF and is a good prognostic sign.²⁷³ If cardiac function fails to improve, it is important to also consider additional contributory factors, such as other cardiomyopathy or other concomitant pathology. It is likely that trends in cardiac T2* have similar importance for prognosis, but this has not been addressed in published studies. Where T2* CMR is not readily available, serial cardiac function measurements become paramount as an important indicator for increased risk of HF from cardiac iron overload.

12. Cardiac Mortality and Iron Chelation

The introduction of deferoxamine infusion in the 1970s had a profound effect on reducing mortality in TM,^{2,277} and this was dominated by a reduction in iron overload-related cardiac mortality. More recently, deferiprone was introduced into clinical care in many countries (European approval in 1999 and US Food and Drug Administration approval in 2011), either as monotherapy or in combination with deferoxamine. Its use has been associated with reduced cardiac mortality in the United Kingdom, Italy, Cyprus, and Hong Kong.^{11,14,249,250,268,278,279} In the United Kingdom, treatment with deferiprone has been linked to the finding of normal cardiac iron concentration with cardiac T2* >20 ms.²⁴⁰ The mechanism for the improved mortality is probably multifactorial but may include early identification of patients at cardiac risk by cardiac T2*, improved compliance with chelation therapy, or specific cardiac actions of deferiprone, including greater access to cardiac iron stores or mitochondrial iron. There have been no reports since the introduction of deferasirox (US Food

and Drug Administration approval in 2005) that have documented any effects on cardiac mortality in TM.

13. Pregnancy

Recent advances in the management of TM have substantially reduced complications and improved quality of life and life expectancy of patients, with a consequent increase in their reproductive potential and desire to have children. An increasing number of women with TM have a successful pregnancy, with >500 pregnancies reported.^{22,280–283} Spontaneous fertility can occur in well-transfused and chelated women with TM. Unfortunately, the majority have impaired fertility caused by hypogonadism and require induction of ovulation, which may produce a high number of twin or triplet pregnancies.^{283–286} The maternal and fetal risks depend primarily on preexisting maternal complications and iron-related organ damage.²⁸⁷ Iron overload may result in cardiac complications, and therefore, we recommend assessment of heart T2* and cardiac function and dimensions before conception. Blood consumption may increase during pregnancy to maintain a hemoglobin level of ≈ 10 g/dL and ensure optimal fetal growth,²⁸³ and when combined with the interruption of chelation because of teratogenic considerations, this may significantly worsen iron overload. These factors, the increased blood volume and changes in blood pressure, may compromise heart function, which should be monitored carefully during pregnancy.

The rate of cardiac complications in pregnancy ranges from 1.1% to 15.6%.^{284,288} In patients with severe heart or liver iron overload, a restarting of iron chelation with deferoxamine toward the end of the second trimester should be considered. Spontaneous miscarriage and fetal loss have been reported in 9% to 33.3% of pregnancies in women with thalassemia.^{285,289} Preterm births for underlying maternal or obstetric complications have occurred at increased rates. Obstetric complications, including gestational diabetes, preeclampsia, and hypertension, have been reported frequently.²⁸⁷ The rate of cesarean delivery because of fetopelvic disproportion, osteoporosis, maternal HIV infection, or patient choice varies between 24% and 100%.^{283,284} Prophylaxis for thromboembolism with heparin or low-molecular-weight heparin is indicated, particularly in splenectomized patients and in patients with thalassemia intermedia. In conclusion, provided that a multidisciplinary team is available, pregnancy is possible with a favorable outcome, but such pregnancies are best handled in expert centers because of the increased risk to mother and baby, especially in women who have preexisting cardiac disease or large amounts of cardiac iron.

14. Late Consequences of Transfusion

14.1 Arrhythmias and Iron Loading

From the earliest reporting of the cardiovascular complications of thalassemia, it was noted that arrhythmia and conduction disturbance were featured prominently.²⁷ AF was the most common arrhythmia (12 of 20) encountered in transfused but not chelated patients, with ventricular arrhythmias being less common (2 of 20). Abnormalities of conduction disturbance from complete heart block (4 of 20) to more minor electrocardiographic abnormalities were also seen (15 of 20).²⁷ The

follow-up of this cohort revealed that 50% of patients had cardiac rhythm disturbances by the age of 20 years, and 40% developed heart block, although this complication was uncommon (6%) before the age of 15 years.⁴⁵ Early pathological examination of hearts affected by iron overload emphasized the patchiness of iron overload,⁷² with evidence of atrioventricular nodal and conducting tissue having variable iron content that was not always associated with clinical evidence of arrhythmia or heart block.²¹⁰ A role of severe, untreated iron overload in the development of conduction disturbance would appear likely. The incidence of heart block has diminished drastically with effective chelation therapy in TM patients.²⁹⁰ In a prospective series, $\approx 14\%$ of patients with severe iron overload (T2* <6 ms) experienced an arrhythmia within 1 year of the CMR scan; most of these arrhythmias were AF (78 of 98 patients), although a few patients had ventricular arrhythmia (5/98), including 1 patient who died.⁶ Arrhythmias may occur in patients with normal myocardial T2*,⁶ and a number of explanations for this finding are possible, including the existence of atrial iron loading separate from the ventricle, vulnerability of the atria to arrhythmias, persistence of atrial iron loading despite ventricular clearance, myocarditis, and the longstanding proarrhythmic atrial effects of volume loading and high cardiac output caused by chronic anemia.

14.2 Arrhythmias in Relation to HF

Arrhythmias in TM may be a consequence of the development of HF, may precipitate HF, or may occur in the context of good LV function with or without current evidence of iron overload. This is particularly the case for AF; in the aging cohort of well-chelated individuals, AF may be encountered in otherwise apparently healthy hearts. Ventricular arrhythmia is more often associated with severe iron overload, although this distinction between acute presentations and more chronic incidence of arrhythmia has not always been demonstrated.⁶ There are numerous case reports that attest to the association of severe siderotic cardiomyopathy and ventricular arrhythmia, as well as sudden death, assumed to be arrhythmic in origin. The nature of sudden death, by definition, is not clear, but it would be consistent with ventricular arrhythmia as the primary cause in most instances. In this regard, the toxic cardiomyopathy of iron overload would mimic the situation that prevails in other nonischemic and ischemic cardiomyopathies, although the presence of LV dysfunction would not be expected to be a prerequisite for the risk to be elevated in the TM population. The potential mechanisms for such enhanced risk include increased QT dispersion, autonomic dysfunction, high redox potential, and low resting heart rate, and are all to be encountered in more or less severe form in patients with TM.

14.3 Causation of Arrhythmia

Animal studies suggest that the toxicity of iron is first manifest by changes in electrical conduction and arrhythmia, before the onset of contractile failure.²⁹¹ Iron-loaded myocytes have abnormal action potentials, with decreased overshoot and shortened action potential duration compared with non-iron-overloaded cells²¹²; these features are likely to occur in a patchy distribution at a microscopic level and

would be recognized electrical substrates for arrhythmogenesis. In the TM patient, such inhomogeneity of action potential duration would be associated with increased variability of repolarization recorded by the ECG. Increased variability of the QT duration (QT or JT dispersion) has been noted in association with iron overload, and it has been suggested to be a marker for the risk of ventricular arrhythmia and sudden death, presumed to be caused by malignant ventricular arrhythmia.

14.4 Sudden Death

A recent study suggested a high incidence of sudden death among young men without clinical evidence of cardiac disease, with a 27% occurrence rate over a 26-year observation period.²¹⁶ Those who experienced sudden death had ECGs that demonstrated a higher degree of QT and JT dispersion than the cohort who survived. Other groups have not observed such a high incidence of sudden death,^{11,200,290} although sporadic cases are not uncommon in TM. The implications of such increased risk would mandate consideration of the use of implantable cardioverter-defibrillator devices, a prospect not yet considered for the majority of the TM population. There is a need to reassess the thalassemia population for the incidence of electrocardiographic abnormalities that might increase the propensity to malignant ventricular arrhythmia. Careful analysis of the ECG for QT and JT dispersion plus the consideration of “blind” Holter ECG monitoring may be required for subgroups deemed to be at particular risk.

14.5 Treatment of Arrhythmias With Hemodynamic Compromise

Once the diagnosis of ventricular arrhythmia has been made, treatment is urgent and consists of intense, uninterrupted chelation therapy. The evidence, mostly anecdotal, supports the use of deferoxamine by intravenous infusion in a continuous regimen at doses of up to $75 \text{ mg} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$ or more.^{47,48,292,293} In general, patients are supported at these times by concurrent treatment with antiarrhythmic medication, which in this context usually consists of an infusion of amiodarone by central vein.²⁹⁴ Alternative medication, such as β -blockers and class I antiarrhythmic agents, are usually ruled out by hypotension in the decompensated TM patient. Adjunctive supportive treatment would include normalization of electrolyte deficiencies, particularly potassium (target $>4.5 \text{ mmol/L}$), and the infusion of magnesium,^{295,296} plus careful management of associated endocrine abnormalities, such as diabetes mellitus, hypoparathyroidism, and thyroid disorders. Blood glucose should be maintained within appropriate ranges ($4.0\text{--}6.0 \text{ mmol/L}$) by flexible, sliding-scale insulin infusions. In hemodynamically compromised patients, direct current defibrillation may be required.

For acute AF complicated by hemodynamic compromise, for overt HF, or in the context of known severe myocardial iron overload (pragmatic definition of $T2^* <10 \text{ ms}$), the immediate approach should be the same as for ventricular arrhythmia. In both instances, there should be attention given to anticoagulation. There is at least a theoretical potential for systemic embolization for these patients because of the

combined features of the arrhythmia, possibly enlarged atrial size, and procoagulant features of the hematologic condition, exacerbated in many by asplenia.^{297–299}

14.6 Treatment of Arrhythmias in Ambulatory Patients

In many of the aging population of thalassemia patients, even in those with current excellent iron status and good ventricular function, paroxysmal supraventricular tachycardia and AF in particular are frequently encountered in the clinic. The precise incidence and associated features of this growing population are not yet clear. The management of AF for this group should parallel that advocated for the general population, in whom AF is seen increasingly more often in the aging population, albeit at considerably older ages than for the TM group. Strategies for managing paroxysmal AF, persistent AF, and established, permanent AF revolve around the choices of rhythm control versus acceptance of the arrhythmia, with attention directed to rate control. Special considerations apply to the TM patient. The general population's attributable risk of systemic embolization (mostly manifest by stroke) cannot be assumed to apply. It is possible that the risk of stroke in this significantly younger group would be increased by virtue of the documented prothrombotic tendencies. Permanent anticoagulation would need to be considered at an early stage for all but the mildly affected group, who experience infrequent, short-lasting bouts of AF. For those patients intolerant of antiarrhythmic drugs and those whose AF is poorly controlled despite the use of such medication, consideration should be given to the newer techniques used to control arrhythmia. Ablation techniques have evolved into a mainstay of treatment for AF patients who fall into the above categories. Currently, success rates for AF are quoted as being between 70% and 80% for the eradication of the arrhythmia, albeit with a 10% to 15% likelihood of requiring >1 ablation procedures.^{300,301} The pathophysiology of supraventricular tachycardia and AF in the TM population may be different, so that equivalent success rates seen in the general population of AF patients should not be assumed to apply to this special group. On the positive side, TM patients are likely to be younger, but to counterbalance this, the atria may be much more difficult to treat by virtue of the widespread but patchy distribution of fibrosis and residual iron deposits. Patients with TM must not be denied the possibility of ablation treatment, but caution needs to be expressed with regard to longer-term outcome until more prospective data become available, most likely through registries rather than formal trials.

Although heart block was documented in early series of iron-overloaded patients,³⁰² this complication has all but disappeared with better treatment. However, sporadic cases do occur and will require the use of pacemakers. Historically, this would have meant the loss of the ability to use CMR in these individuals; however, manufacturers have now successfully produced pacemakers and leads that are compatible for use in MR scanners.³⁰³ The units carry a specific x-ray opaque identification marker to allow confirmation that an MR-safe pacemaker is in place before any scan, should the patient's details not be known to the imaging unit.

14.7 Liver Disease

Liver disease is frequent in TM because of transfusion-transmitted hepatitis and iron overload. Chronic hepatitis C infection is the most common form of hepatitis infection worldwide, whereas infection with hepatitis B virus is more prevalent in Asia.³⁰⁴ In many countries, the incidence of both infections in thalassemia fell significantly in the 1990s with the screening of blood donors and the hepatitis B virus vaccine. Today, the residual risk of transfusion-transmitted infection is <2 per 1 million,³⁰⁵ whereas the prevalence of chronic hepatitis C is high in patients born before 1990. Both viral hepatitis and iron overload are independently associated with liver fibrosis, cirrhosis, end-stage liver disease, and hepatocellular carcinoma. When both factors are present, as in TM, the effect is synergistic, and in the individual patient, it may be impossible to distinguish the role of each. The prevalence of cirrhosis in adult TM patients ranges from 10% to 20%.³⁰⁶ Cirrhosis predisposes to long-term end-stage liver failure and is the main risk factor for hepatocellular carcinoma. Once rare, hepatocellular carcinoma now has a rising prevalence in TM.^{307–310}

14.8 Renal Disease

Awareness of underlying renal dysfunction is critical because it is a surrogate and independent marker for an increased risk of stroke, HF, and myocardial infarction.³¹¹ With increasing patient survival, renal disease has become more prevalent in patients with TM. Various abnormalities of renal function, including both glomerular and tubular dysfunction, have been reported,^{312–314} but there are no systemic longitudinal studies. A recent cross-sectional study in TM patients has shown an abnormally high creatinine clearance in 20.8%, low creatinine clearance in 7.8%, hypercalciuria in 28.7%, and albuminuria in up to 59% of patients.³¹⁵ Mechanisms of kidney dysfunction are numerous and only partially clarified, but chronic anemia, hypoxia, iron, and iron chelators are potentially toxic to renal parenchyme.³¹⁶ Acute kidney injury has also been reported,

and the probable mechanism in many cases is prerenal from sepsis or complications of HF (cardiorenal syndrome) and liver failure that affects renal perfusion. Labile iron may also lead to acute kidney injury.^{317,318} Several renal side effects have been reported in association with the use of deferoxamine and deferasirox. Deferoxamine causes acute renal dysfunction at high doses or at normal doses in high-risk patients (those with diabetes mellitus, hypertension, or proteinuria; elderly patients; and those with underlying renal dysfunction), especially when given intravenously.^{319–321} Deferasirox has been associated with several renal side effects, including nonprogressive increases in serum creatinine and cases of reversible mild or even life-threatening Fanconi syndrome.^{139,322–327}

15. Future Directions

There are ongoing clinical trials that are relevant to treatment of cardiac iron overload by deferasirox. One that is relevant is the Novartis 2214 trial, with open-label treatment in TM patients with combined deferoxamine with deferasirox. In addition, clinical trials of new chelators are ongoing. There are many unanswered questions in the management and treatment of cardiac disease in TM patients. The most obvious general gap relates to the relative paucity of high-quality studies of large sample sizes to determine treatment preferences. However, there is also a need to better understand trends (as opposed to absolute values) in iron biomarkers as prognostic indicators. The clinical importance of endothelial dysfunction in iron overload needs clarifying. The possible clinical value of complex, more fragile measurements of iron components by CMR, other than hemosiderin (such as ferritin), needs evaluation.³²⁸ The application of noninvasive iron measurement technology needs to be evaluated in other iron-overload conditions after a report of its use in hereditary hemochromatosis.³²⁹ Finally, a randomized controlled trial of long-term amlodipine treatment, which is a new strategy to prevent cardiac iron loading, is under way.^{61,330}

Disclosures

Writing Group Disclosures

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Dudley J. Pennell	National Heart and Lung Institute, Imperial College (London, UK)	AMAG†; Apotex†; NIHR†; Novartis†; Siemens†	None	None	None	CVIS*	AMAG*; Apotex†; Novartis†; Shire*; Siemens†	None
James E. Udelson	Tufts Medical Center	None	None	None	None	None	None	None
Andrew E. Arai	NIH	None	None	None	None	None	None	None
Biykem Bozkurt	Michael E. DeBakey VA Medical Center/ Baylor College of Medicine	NIH†	None	None	None	None	None	None
Alan R. Cohen	University of Pennsylvania and Children's Hospital of Philadelphia	ApoPharma†; Novartis†	None	None	None	None	None	None
Renzo Galanello	University of Cagliari/ Novartis (Italy)	ApoPharma†; Novartis†	None	ApoPharma*; Novartis*	None	None	Novartis*	None
Timothy M. Hoffman	Nationwide Children's Hospital	None	None	None	None	None	None	None
Michael S. Kiernan	Tufts Medical Center	None	None	None	None	None	None	None
Stamatis Lerakis	Emory Healthcare	None	None	None	None	None	None	None
Antonio Piga	University of Turin (Italy)	ApoPharma†; Novartis†	None	ApoPharma†; Novartis*	None	None	Novartis†	None
John B. Porter	University College Hospital of London, UK	Educational grant from Novartis†	None	Novartis†	None	None	Novartis†	None
John Malcolm Walker	University College Hospital NHS Foundation Trust (London, UK)	None	None	None	None	None	None	None
John Wood	Children's Hospital of Los Angeles	California Institute of Regenerative Medicine†; CDC†; Codey's American Foundation†; NIH†; Novartis†	None	None	None	None	ApoPharma*; Ferrokina Biosciences†; Novartis*; Shire†	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (1) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

*Modest.

†Significant.

Reviewer Disclosures

Reviewer	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
James H. Abernathy	Medical University of South Carolina	None	None	None	None	None	None	None
Massimo Lombardi	Institute of Clinical Physiology, Pisa, Italy	None	None	None	None	None	None	None
Ellis Neufeld	Boston Children's Hospital	None	None	None	None	None	None	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be "significant" if (1) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

Acknowledgment

This paper is dedicated to the memory of Professor Renzo Galanello, whose recent passing has deprived his colleagues and patients of his abundant wisdom and humanity.

References

- Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. *Haematologica*. 2004;89:1187–1193.
- Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. *Lancet*. 2000;355:2051–2052.
- Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, Pavlides N, Psiloinis M, Simamonian K, Skordos G, Sitarou M, Angastiniotis M. Survival of medically treated thalassemia patients in Cyprus: trends and risk factors over the period 1980–2004. *Haematologica*. 2006;91:1187–1192.
- Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. *Ann NY Acad Sci*. 2005;1054:445–450.
- Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. *Eur Heart J*. 2001;22:2171–2179.
- Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, Wu D, Taylor J, Westwood MA, Anderson LJ, Pennell DJ. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. *Circulation*. 2009;120:1961–1968.
- Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, Sheppard MN, Porter JB, Walker JM, Wood JC, Galanello R, Forni G, Catani G, Matta G, Fucharoen S, Fleming A, House MJ, Black G, Firmin DN, St Pierre TG, Pennell DJ. On T2* magnetic resonance and cardiac iron. *Circulation*. 2011;123:1519–1528.
- Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. *Blood*. 2006;107:3738–3744.
- Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. *Circulation*. 2007;115:1876–1884.
- Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, Elalfy MS, Sutcharitchan P, Li CK, Ibrahim H, Viprakasit V, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. *Blood*. 2010;115:2364–2371.
- Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. *J Cardiovasc Magn Reson*. 2008;10:42.
- Telfer P. Update on survival in thalassemia major. *Hemoglobin*. 2009;33(suppl 1):S76–S80.
- Chouliaras G, Berdoukas V, Ladis V, Kattamis A, Chatziliami A, Fragodimitri C, Karabatsos F, Youssef J, Karagiorga-Lagana M. Impact of magnetic resonance imaging on cardiac mortality in thalassemia major. *J Magn Reson Imaging*. 2011;34:56–59.
- Au WY, Lee V, Lau CW, Yau J, Chan D, Chan EY, Cheung WW, Ha SY, Kho B, Lee CY, Li RC, Li CK, Lin SY, Ling AS, Mak V, Sun L, Wong KH, Wong R, Yuen HL. A synopsis of current care of thalassaemia major patients in Hong Kong. *Hong Kong Med J*. 2011;17:261–266.
- Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. *Br J Haematol*. 2007;138:407–421.
- Mamtani M, Kulkarni H. Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis. *Br J Haematol*. 2008;141:882–890.
- Cogliandro T, Derchi G, Mancuso L, Mayer MC, Mannone B, Pepe A, Pili M, Bina P, Cianciulli P, De Sanctis V, Maggio A; Society for the Study of Thalassemia and Hemoglobinopathies (SoSTE). Guideline recommendations for heart complications in thalassemia major. *J Cardiovasc Med (Hagerstown)*. 2008;9:515–525.
- Aessopos A, Kati M, Tsironi M. Congestive heart failure and treatment in thalassemia major. *Hemoglobin*. 2008;32:63–73.
- Aessopos A, Berdoukas V, Tsironi M. The heart in transfusion dependent homozygous thalassaemia today: prediction, prevention and management. *Eur J Haematol*. 2008;80:93–106.
- Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice. *Circulation*. 2011;124:2253–2263.
- Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E. Liver iron concentrations and urinary hepcidin in beta-thalassemia. *Haematologica*. 2007;92:583–588.
- Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR; Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. *Blood*. 2004;104:34–39.
- Aessopos A, Tsironi M, Andreopoulos A, Farmakis D. Heart disease in thalassemia intermedia. *Hemoglobin*. 2009;33(suppl 1):S170–S176.
- Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. *Blood Rev*. 2012;26(suppl 1):S16–S19.
- Voskaridou E, Christoulas D, Terpos E. Sickle-cell disease and the heart: review of the current literature. *Br J Haematol*. 2012;157:664–673.
- Cappellini M-D, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. *Guidelines for the Clinical Management of Thalassemia*. 2nd ed rev. Nicosia, Cyprus: Thalassaemia International Federation; 2008.
- Engle MA, Erlanson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. *Circulation*. 1964;30:698–705.
- Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous beta-thalassemia. *N Engl J Med*. 1994;331:574–578.
- Charafeddine K, Isma'eel H, Charafeddine M, Inati A, Koussa S, Naja M, Taher A. Survival and complications of beta-thalassemia in Lebanon: a decade's experience of centralized care. *Acta Haematol*. 2008;120:112–116.
- Modell B. The management of the improved prognosis in thalassemia major. *Birth Defects Orig Artic Ser*. 1982;18:329–337.
- Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevisi C, Di Gregorio F, Burattini MG, Terzoli S. Survival and causes of death in thalassaemia major. *Lancet*. 1989;2:27–30.
- Ladis V, Chouliaras G, Berdoukas V, Chatziliami A, Fragodimitri C, Karabatsos F, Youssef J, Kattamis A, Karagiorga-Lagana M. Survival in a large cohort of Greek patients with transfusion-dependent beta thalassaemia and mortality ratios compared to the general population. *Eur J Haematol*. 2011;86:332–338.
- Au WY, Lam WW, Chu WW, Yuen HL, Ling AS, Li RC, Chan HM, Lee HK, Law MF, Liu HS, Liang R, Ha SY. A cross-sectional magnetic resonance imaging assessment of organ specific hemosiderosis in 180 thalassemia major patients in Hong Kong. *Haematologica*. 2008;93:784–786.
- Aypar E, Alehan D, Hazirolan T, Gümrük F. The efficacy of tissue Doppler imaging in predicting myocardial iron load in patients with beta-thalassemia major: correlation with T2* cardiovascular magnetic resonance. *Int J Cardiovasc Imaging*. 2010;26:413–421.
- Patton N, Brown G, Leung M, Bavishi K, Taylor J, Lloyd J, Lee SH, Tay L, Worthley S. Observational study of iron overload as assessed by magnetic resonance imaging in an adult population of transfusion-dependent patients with beta thalassaemia: significant association between low cardiac T2* < 10 ms and cardiac events. *Intern Med J*. 2010;40:419–426.
- Daar S, Pathare AV, Jain R, Zadjali SA, Pennell DJ. T2* cardiovascular magnetic resonance in the management of thalassemia patients in Oman. *Haematologica*. 2009;94:140–141.
- Kwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichinsky EP, Boudreaux JM, Cohen AR, Porter JB, Coates T, Olivieri NF, Neufeld EJ; Thalassemia Clinical Research Network. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. *Blood*. 2012;119:2746–2753.
- Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Nair SV, Anderson LJ, Walker JM, Pennell DJ. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. *J Cardiovasc Magn Reson*. 2006;8:543–547.
- Positano V, Pepe A, Santarelli MF, Ramazzotti A, Meloni A, De Marchi D, Favilli B, Cracolici E, Midiri M, Spasiano A, Lombardi M, Landini L. Multislice multiecho T2* cardiac magnetic resonance for the detection of

- heterogeneous myocardial iron distribution in thalassaemia patients. *NMR Biomed.* 2009;22:707–715.
40. Aessopos A, Fragodimitri C, Karabatsos F, Hatziliami A, Yousef J, Giakoumis A, Dokou A, Gotsis ED, Berdoukas V, Karagiorga M. Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. *Haematologica.* 2007;92:131–132.
 41. Carpenter JP, Roughton M, Pennell DJ. International survey of T2* cardiovascular magnetic resonance in thalassemia. *Haematologica.* 2012;97(e-suppl 1):248–249.
 42. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, Sabato V, Melevendi C, Cappellini MD, Verlato G. Survival and disease complications in thalassemia major. *Ann NY Acad Sci.* 1998;850:227–231.
 43. Marsella M, Borgna-Pignatti C, Meloni A, Caldarelli V, Dell'Amico MC, Spasiano A, Pitrolo L, Cracolici E, Valeri G, Positano V, Lombardi M, Pepe A. Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2* magnetic resonance imaging study. *Haematologica.* 2011;96:515–520.
 44. Engle MA. Cardiac involvement in Cooley's anemia. *Ann NY Acad Sci.* 1964;119:694–702.
 45. Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. *J Pediatr.* 1991;118(pt 1):540–545.
 46. Kremastinos DT, Tsetsos GA, Tsiapras DP, Karavolias GK, Ladis VA, Kattamis CA. Heart failure in beta thalassemia: a 5-year follow-up study. *Am J Med.* 2001;111:349–354.
 47. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. *Br J Haematol.* 2004;127:348–355.
 48. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. *Blood.* 2000;95:1229–1236.
 49. Miskin H, Yaniv I, Berant M, Hershko C, Tamary H. Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. *Eur J Haematol.* 2003;70:398–403.
 50. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. *J Cardiovasc Magn Reson.* 2008;10:12.
 51. Thomas AS, Garbowski M, Ang AL, Shah FT, Walker JM, Moon JC, Pennell DJ, Porter JB. A decade follow-up of a thalassemia major (TM) cohort monitored by cardiac magnetic resonance imaging (CMR): significant reduction in patients with cardiac iron and in total mortality. *Blood (ASH Annual Meeting Abstracts).* 2010;116:Abstract 1011.
 52. Di Tucci AA, Matta G, Deplano S, Gabbas A, Depau C, Derudas D, Caocci G, Agus A, Angelucci E. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. *Haematologica.* 2008;93:1385–1388.
 53. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. *Blood.* 2004;103:1934–1936.
 54. Wood JC, Origa R, Agus A, Matta G, Coates TD, Galanello R. Onset of cardiac iron loading in pediatric patients with thalassemia major. *Haematologica.* 2008;93:917–920.
 55. Fernandes JL, Fabron A Jr, Verissimo M. Early cardiac iron overload in children with transfusion-dependent anemias. *Haematologica.* 2009;94:1776–1777.
 56. Ludwiczek S, Theurl I, Muckenthaler MU, Jakab M, Mair SM, Theurl M, Kiss J, Paulmichl M, Hentze MW, Ritter M, Weiss G. Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1. *Nat Med.* 2007;13:448–454.
 57. Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, Yazdanpanah M, Wilson GJ, Schwartz A, Liu PP, Backx PH. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. *Nat Med.* 2003;9:1187–1194.
 58. Kumfu S, Chattipakorn S, Chinda K, Fucharoen S, Chattipakorn N. T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice. *Eur J Haematol.* 2012;88:535–548.
 59. Kumfu S, Chattipakorn S, Fucharoen S, Chattipakorn N. Ferric iron uptake into cardiomyocytes of β -thalassemic mice is not through calcium channels. *Drug Chem Toxicol.* 2013;36:329–334.
 60. Link G, Pinson A, Hershko C. Heart cells in culture: a model of myocardial iron overload and chelation. *J Lab Clin Med.* 1985;106:147–153.
 61. Fernandes JL, Sampaio EF, Fertrin K, Coelho OR, Loggetto S, Piga A, Verissimo M, Saad ST. Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial. *Am J Med.* In press.
 62. Anderson LJ, Westwood MA, Prescott E, Walker JM, Pennell DJ, Wonke B. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. *Acta Haematol.* 2006;115:106–108.
 63. Wu KH, Chang JG, Ho YJ, Wu SF, Peng CT. Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with beta-thalassemia major. *Hemoglobin.* 2006;30:251–256.
 64. Origa R, Satta S, Matta G, Galanello R. Glutathione S-transferase gene polymorphism and cardiac iron overload in thalassaemia major. *Br J Haematol.* 2008;142:143–145.
 65. Flanagan JM, Steward S, Hankins JS, Howard TM, Neale G, Ware RE. Microarray analysis of liver gene expression in iron overloaded patients with sickle cell anemia and beta-thalassemia. *Am J Hematol.* 2009;84:328–334.
 66. Murphy CJ, Oudit GY. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. *J Card Fail.* 2010;16:888–900.
 67. Hershko C. Pathogenesis and management of iron toxicity in thalassemia. *Ann NY Acad Sci.* 2010;1202:1–9.
 68. Link G, Pinson A, Hershko C. Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells. *Blood.* 1994;83:2692–2697.
 69. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the “iron shuttle” hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. *J Lab Clin Med.* 2001;138:130–138.
 70. Wood JC, Enriquez C, Ghugre N, Otto-Duessel M, Aguilar M, Nelson MD, Moats R, Coates TD. Physiology and pathophysiology of iron cardiomyopathy in thalassemia. *Ann NY Acad Sci.* 2005;1054:386–395.
 71. Kim E, Giri SN, Pessah IN. Iron(II) is a modulator of ryanodine-sensitive calcium channels of cardiac muscle sarcoplasmic reticulum. *Toxicol Appl Pharmacol.* 1995;130:57–66.
 72. Buja LM, Roberts WC. Iron in the heart: etiology and clinical significance. *Am J Med.* 1971;51:209–221.
 73. Kirk P, Sheppard M, Carpenter J, Anderson L, He T, De Noronha S, St Pierre T, Galanello R, Catani G, Wood J, Fucharoen S, Porter J, Walker JM, Forni G, Pennell D. Fibrosis in cardiac siderosis: update on historical perspectives. *Haematologica.* 2012;97(e-Suppl 1):382.
 74. Eaton JW, Qian M. Molecular bases of cellular iron toxicity. *Free Radic Biol Med.* 2002;32:833–840.
 75. Veglio F, Melchio R, Rabbia F, Molino P, Genova GC, Martini G, Schiavone D, Piga A, Chiandussi L. Blood pressure and heart rate in young thalassemia major patients. *Am J Hypertens.* 1998;11:539–547.
 76. Li W, Coates T, Wood JC. Atrial dysfunction as a marker of iron cardiotoxicity in thalassemia major. *Haematologica.* 2008;93:311–312.
 77. Pepe A, Positano V, Capra M, Maggio A, Pinto CL, Spasiano A, Forni G, Derchi G, Favilli B, Rossi G, Cracolici E, Midiri M, Lombardi M. Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major. *Heart.* 2009;95:1688–1693.
 78. Kirk P, Carpenter JP, Tanner MA, Pennell DJ. Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance. *J Cardiovasc Magn Reson.* 2011;13:8.
 79. Omura T, Yoshiyama M, Hayashi T, Nishiguchi S, Kaito M, Horiike S, Fukuda K, Inamoto S, Kitaura Y, Nakamura Y, Teragaki M, Tokuhisa T, Iwao H, Takeuchi K, Yoshikawa J. Core protein of hepatitis C virus induces cardiomyopathy. *Circ Res.* 2005;96:148–150.
 80. Trikas A, Tentolouris K, Katsimakis G, Antoniou J, Stefanadis C, Toutouzias P. Exercise capacity in patients with beta-thalassemia major: relation to left ventricular and atrial size and function. *Am Heart J.* 1998;136:988–990.
 81. Hamdy AM, Zein El-Abdin MY, Abdel-Hafez MA. Right ventricular function in patients with beta thalassemia: relation to serum ferritin level. *Echocardiography.* 2007;24:795–801.
 82. Cheung YF, Chan GC, Ha SY. Arterial stiffness and endothelial function in patients with beta-thalassemia major. *Circulation.* 2002;106:2561–2566.
 83. Cheung YF, Chan GC, Ha SY. Effect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia major. *Br J Haematol.* 2008;141:728–733.

84. Kukongviriyapan V, Somporn N, Senggunprai L, Prawan A, Kukongviriyapan U, Jetsrisuparb A. Endothelial dysfunction and oxidant status in pediatric patients with hemoglobin E-beta thalassemia. *Pediatr Cardiol*. 2008;29:130–135.
85. Vogel M, Anderson LJ, Holden S, Deanfield JE, Pennell DJ, Walker JM. Tissue Doppler echocardiography in patients with thalassaemia detects early myocardial dysfunction related to myocardial iron overload. *Eur Heart J*. 2003;24:113–119.
86. Marci M, Pitrolo L, Lo Pinto C, Sanfilippo N, Malizia R. Detection of early cardiac dysfunction in patients with beta thalassemia by tissue Doppler echocardiography. *Echocardiography*. 2011;28:175–180.
87. Westwood MA, Wonke B, Maceira AM, Prescott E, Walker JM, Porter JB, Pennell DJ. Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major. *J Magn Reson Imaging*. 2005;22:229–233.
88. Stakos DA, Margaritis D, Tziakas DN, Kotsianidis I, Chalikias GK, Tsatalas K, Bourikas G, Boudoulas H. Cardiovascular involvement in patients with beta-thalassemia major without cardiac iron overload. *Int J Cardiol*. 2009;134:207–211.
89. Mancuso L, Mancuso A, Bevacqua E, Rigano P. Electrocardiographic abnormalities in thalassemia patients with heart failure. *Cardiovasc Hematol Disord Drug Targets*. 2009;9:29–35.
90. Ramazzotti A, Pepe A, Positano V, Scattini B, Santarelli MF, Landini L, De Marchi D, Keilberg P, Derchi G, Formisano F, Pili M, Lai ME, Forni G, Filosa A, Prossomariti L, Capra M, Pitrolo L, Borgna-Pignatti C, Cianciulli P, Maggio A, Lombardi M. Standardized T2* map of a normal human heart to correct T2* segmental artefacts: myocardial iron overload and fibrosis in thalassemia intermedia versus thalassemia major patients and electrocardiogram changes in thalassemia major patients. *Hemoglobin*. 2008;32:97–107.
91. Detterich J, Noetzi L, Dorey F, Bar-Cohen Y, Harmatz P, Coates T, Wood J. Electrocardiographic consequences of cardiac iron overload in thalassemia major. *Am J Hematol*. 2012;87:139–144.
92. Kremastinos DT, Hamodraka E, Parissis J, Tsiapras D, Dima K, Maisel A. Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in beta-thalassemia major. *Am Heart J*. 2010;159:68–74.
93. Delaporta P, Kattamis A, Apostolou F, Boiu S, Bartzeliotou A, Tsoukas E, Papassotiriou I. Correlation of NT-proBNP levels and cardiac iron concentration in patients with transfusion-dependent thalassemia major. *Blood Cells Mol Dis*. 2013;50:20–24.
94. Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland JG, Pennell DJ. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? *Eur Heart J*. 2000;21:1387–1396.
95. Giakoumis A, Berdoukas V, Gotsis E, Aessopos A. Comparison of echocardiographic (US) volumetry with cardiac magnetic resonance (CMR) imaging in transfusion dependent thalassemia major (TM). *Cardiovasc Ultrasound*. 2007;5:24.
96. Hahalis G, Kourakli A, Gerasimidou I, Kalogeropoulos AP, Sifafidis G, Papageorgiou U, Davlouros P, Grapsas N, Zombos NC, Alexopoulos D. Cardiac mortality in {beta}-thalassaemia major: resting but not dobutamine stress echocardiography predicts mortality among initially cardiac disease-free patients in a prospective 12-year study. *Eur J Heart Fail*. 2009;11:1178–1181.
97. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. *J Am Soc Echocardiogr*. 2009;22:107–133.
98. Leon MB, Borer JS, Bacharach SL, Green MV, Benz EJ Jr, Griffith P, Nienhuis AW. Detection of early cardiac dysfunction in patients with severe beta-thalassemia and chronic iron overload. *N Engl J Med*. 1979;301:1143–1148.
99. Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. *J Cardiovasc Magn Reson*. 2006;8:417–426.
100. Maceira AM, Prasad SK, Khan M, Pennell DJ. Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance. *Eur Heart J*. 2006;27:2879–2888.
101. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, Pennell DJ. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. *Am J Cardiol*. 2002;90:29–34.
102. Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, Pennell DJ. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. *Am Heart J*. 2004;147:218–223.
103. Westwood MA, Anderson LJ, Maceira AM, Shah FT, Prescott E, Porter JB, Wonke B, Walker JM, Pennell DJ. Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. *J Magn Reson Imaging*. 2007;25:1147–1151.
104. Carpenter JP, Alpendurada F, Deac M, Maceira A, Garbowski M, Kirk P, Walker JM, Porter JB, Shah F, Banya W, He T, Smith GC, Pennell DJ. Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload. *J Cardiovasc Magn Reson*. 2010;12:24.
105. Fernandes JL, Silveira MA, Fertrin K, Lauer S, Fattori A, Coelho O, Junqueira FP, da Cunha GM, Coutinho AC Jr, Pereira FB, Verissimo M, Saad ST. Left and right ventricular function and volume assessment in young thalassemia major patients with no related myocardial iron overload. *Ann Hematol*. 2012;91:1839–1844.
106. Meloni A, Detterich J, Berdoukas V, Pepe A, Lombardi M, Coates TD, Wood JC. Comparison of biventricular dimensions and function between pediatric sickle-cell disease and thalassemia major patients without cardiac iron. *Am J Hematol*. 2013;88:213–218.
107. Roghi A, Dellegrottaglie S, Pedrotti P, Pedretti S, Cassinerio E, Cappellini MD. Unexpected myocarditis in thalassaemia major patient screened for iron load cardiomyopathy. *BMJ Case Rep*. 2009;2009:bcr08.2008.0811.
108. Rathi VK, Doyle M, Yamrozik J, Williams RB, Caruppanan K, Truman C, Vido D, Biederman RW. Routine evaluation of left ventricular diastolic function by cardiovascular magnetic resonance: a practical approach. *J Cardiovasc Magn Reson*. 2008;10:36.
109. Plein S, Schulz-Menger J, Almeida A, Mahrholdt H, Rademakers F, Pennell D, Nagel E, Schwitler J, Lombardi M; Working Group on Cardiovascular Magnetic Resonance, European Society of Cardiology. Training and accreditation in cardiovascular magnetic resonance in Europe: a position statement of the working group on cardiovascular magnetic resonance of the European Society of Cardiology. *Eur Heart J*. 2011;32:793–798.
110. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E; Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized Protocols. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, Society for Cardiovascular Magnetic Resonance: Board of Trustees Task Force on Standardized Protocols. *J Cardiovasc Magn Reson*. 2008;10:35.
111. Maffei E, Messalli G, Martini C, Nieman K, Catalano O, Rossi A, Seitun S, Guaricci AI, Tedeschi C, Mollet NR, Cademartiri F. Left and right ventricle assessment with cardiac CT: validation study vs. cardiac MR. *Eur Radiol*. 2012;22:1041–1049.
112. Wood JC, Mo A, Gera A, Koh M, Coates T, Gilsanz V. Quantitative computed tomography assessment of transfusional iron overload. *Br J Haematol*. 2011;153:780–785.
113. Westwood MA, Anderson LJ, Firmin DN, Gatehouse PD, Lorenz CH, Wonke B, Pennell DJ. Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia. *J Magn Reson Imaging*. 2003;18:616–620.
114. Westwood MA, Firmin DN, Gildo M, Renzo G, Stathis G, Markissia K, Vasili B, Pennell DJ. Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. *Int J Cardiovasc Imaging*. 2005;21:531–538.
115. Kirk P, He T, Anderson LJ, Roughton M, Tanner MA, Lam WW, Au WY, Chu WC, Chan G, Galanello R, Matta G, Fogel M, Cohen AR, Tan RS, Chen K, Ng I, Lai A, Fucharoen S, Laothamata J, Chuncharunee S, Jongjirasiri S, Firmin DN, Smith GC, Pennell DJ. International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. *J Magn Reson Imaging*. 2010;32:315–319.
116. Fitchett DH, Coltart DJ, Littler WA, Leyland MJ, Trueman T, Gozzard DI, Peters TJ. Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. *Cardiovasc Res*. 1980;14:719–724.
117. Alpendurada F, Carpenter JP, Deac M, Kirk P, Walker JM, Porter JB, Banya W, He T, Smith GC, Pennell DJ. Relation of myocardial T2* to right ventricular function in thalassaemia major. *Eur Heart J*. 2010;31:1648–1654.

118. Westwood M, Anderson LJ, Firmin DN, Gatehouse PD, Charrier CC, Wonke B, Pennell DJ. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. *J Magn Reson Imaging*. 2003;18:33–39.
119. He T, Gatehouse PD, Kirk P, Tanner MA, Smith GC, Keegan J, Mohiaddin RH, Pennell DJ, Firmin DN. Black-blood T2* technique for myocardial iron measurement in thalassemia. *J Magn Reson Imaging*. 2007;25:1205–1209.
120. Smith GC, Carpenter JP, He T, Alam MH, Firmin DN, Pennell DJ. Value of black blood T2* cardiovascular magnetic resonance. *J Cardiovasc Magn Reson*. 2011;13:21.
121. Pepe A, Positano V, Santarelli MF, Sorrentino F, Cracolici E, De Marchi D, Maggio A, Midiri M, Landini L, Lombardi M. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. *J Magn Reson Imaging*. 2006;23:662–668.
122. Ghugre NR, Enriquez CM, Coates TD, Nelson MD Jr, Wood JC. Improved R2* measurements in myocardial iron overload. *J Magn Reson Imaging*. 2006;23:9–16.
123. Ghugre NR, Enriquez CM, Gonzalez I, Nelson MD Jr, Coates TD, Wood JC. MRI detects myocardial iron in the human heart. *Magn Reson Med*. 2006;56:681–686.
124. Wood JC, Noetzli L. Cardiovascular MRI in thalassemia major. *Ann NY Acad Sci*. 2010;1202:173–179.
125. Storey P, Thompson AA, Carqueville CL, Wood JC, de Freitas RA, Rigsby CK. R2* imaging of transfusional iron burden at 3T and comparison with 1.5T. *J Magn Reson Imaging*. 2007;25:540–547.
126. Meloni A, Positano V, Keilberg P, De Marchi D, Pepe P, Zuccarelli A, Campisi S, Romeo MA, Casini T, Bitti PP, Gerardi C, Lai ME, Piraino B, Giuffrida G, Secchi G, Midiri M, Lombardi M, Pepe A. Feasibility, reproducibility, and reliability for the T2* iron evaluation at 3 T in comparison with 1.5 T. *Magn Reson Med*. 2012;68:543–551.
127. Hider RC, Liu ZD. Emerging understanding of the advantage of small molecules such as hydroxypyridinones in the treatment of iron overload. *Curr Med Chem*. 2003;10:1051–1064.
128. Lee P, Mohammed N, Marshall L, Abeyasinghe RD, Hider RC, Porter JB, Singh S. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. *Drug Metab Dispos*. 1993;21:640–644.
129. Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N, Logan W, Mitchell D, Ricci G, Skarf B. Visual and auditory neurotoxicity in patients receiving subcutaneous desferrioxamine infusions. *N Engl J Med*. 1986;314:869–873.
130. Kwiatkowski JL. Management of transfusional iron overload: differential properties and efficacy of iron chelating agents. *J Blood Med*. 2011;2:135–149.
131. Adamkiewicz TV, Berkovitch M, Krishnan C, Polsinelli C, Kermack D, Olivieri NF. Infection due to *Yersinia enterocolitica* in a series of patients with beta-thalassemia: incidence and predisposing factors. *Clin Infect Dis*. 1998;27:1362–1366.
132. Chan GC, Chan S, Ho PL, Ha SY. Effects of chelators (desferrioxamine, deferiprone and deferasirox) on the growth of *Klebsiella pneumoniae* and *Aeromonas hydrophila* isolated from transfusion-dependent thalassemia patients. *Hemoglobin*. 2009;33:352–360.
133. Freedman MH, Grisaru D, Olivieri N, MacLusky I, Thorner PS. Pulmonary syndrome in patients with thalassemia major receiving intravenous desferrioxamine infusions. *Am J Dis Child*. 1990;144:565–569.
134. Galanello R, Campus S. Deferiprone chelation therapy for thalassemia major. *Acta Haematol*. 2009;122:155–164.
135. al-Refaie FN, Sheppard LN, Nortey P, Wonke B, Hoffbrand AV. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. *Br J Haematol*. 1995;89:403–408.
136. Galanello R, Campus S, Origa R. Deferasirox: pharmacokinetics and clinical experience. *Expert Opin Drug Metab Toxicol*. 2012;8:123–134.
137. Nick H. Deferasirox (Exjade, ICL670) preclinical overview. *Semin Hematol* 2007;44(suppl 3):S12–S15.
138. Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, Coates T. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. *Br J Haematol*. 2011;154:387–397.
139. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermeylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. *Blood*. 2006;107:3455–3462.
140. Exjade(deferasirox)USPrescribingInformation.T2013-04.January 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021882s010lbl.pdf. Accessed May 23, 2013.
141. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitzer J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Jung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association (HFA) of the ESC [published correction appears in *Eur J Heart Fail*. 2013;15:361–362]. *Eur J Heart Fail*. 2012;14:803–869.
142. Forni GL, Derchi G. Typical manifestation of acute congestive heart failure in patients with Thalassaemia major causing diagnostic delay in the emergency room. *Eur J Heart Fail*. 2003;5:607–608.
143. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. *Br J Haematol*. 2000;110:971–977.
144. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. *N Engl J Med*. 1994;331:567–573.
145. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferoxamine: indication of close relation between myocardial iron content and chelatable iron pool. *Blood*. 2003;101:4632–4639.
146. Gabutti V, Piga A. Results of long-term iron-chelating therapy. *Acta Haematol*. 1996;95:26–36.
147. Liu Y, Parkes JG, Templeton DM. Differential accumulation of non-transferrin-bound iron by cardiac myocytes and fibroblasts. *J Mol Cell Cardiol*. 2003;35:505–514.
148. Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. *Blood*. 2008;112:2973–2978.
149. Wood JC, Otto-Duessel M, Aguilar M, Nick H, Nelson MD, Coates TD, Pollack H, Moats R. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. *Circulation*. 2005;112:535–543.
150. Collins W, Taylor WH. Determination of iron in cardiac and liver tissues by plasma emission spectroscopy. *Ann Clin Biochem*. 1987;24(pt 5):483–487.
151. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. *Blood*. 2004;104:263–269.
152. Seldrum S, Pierard S, Moniotte S, Vermeylen C, Vancraeynest D, Pasquet A, Vanoverschelde JL, Gerber BL. Iron overload in polytransfused patients without heart failure is associated with subclinical alterations of systolic left ventricular function using cardiovascular magnetic resonance tagging. *J Cardiovasc Magn Reson*. 2011;13:23.
153. Efthimiadis GK, Hassapopoulos HP, Tsikaderis DD, Karvounis HI, Giannakoulas GA, Parharidis GE, Louridas GE. Survival in thalassaemia major patients. *Circ J*. 2006;70:1037–1042.
154. Nanas S, Vasileiadis I, Dimopoulos S, Sakellariou D, Kapsimalakou S, Papazachou O, Tasoulis A, Ladis V, Pangalis G, Aessopos A. New insights into the exercise intolerance of beta-thalassemia major patients. *Scand J Med Sci Sports*. 2009;19:96–102.
155. Mavrogeni S, Gotsis E, Verganelakis D, Berdousis E, Dritsas A, Kolovou G, Toulas P, Ladis V. Effect of iron overload on exercise capacity in

- thalassemic patients with heart failure. *Int J Cardiovasc Imaging*. 2009;25:777–783.
156. Tocco F, Crisafulli A, Melis F, Loviselli A, Lai C, Concu A. Exercise capacity and cardiovascular changes in patients with beta-thalassaemia major. *Clin Physiol Funct Imaging*. 2006;26:319–322.
 157. Vasileiadis I, Roditis P, Dimopoulos S, Ladis V, Pangalis G, Aessopos A, Nanas S. Impaired oxygen kinetics in beta-thalassaemia major patients. *Acta Physiol (Oxf)*. 2009;196:357–363.
 158. Sohn EY, Kato R, Noetzi LJ, Gera A, Coates T, Harmatz P, Keens TG, Wood JC. Exercise performance in thalassemia major: correlation with cardiac iron burden. *Am J Hematol*. 2013;88:193–197.
 159. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur Heart J*. 2008;29:2388–2442.
 160. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2009;119:1977–2016.
 161. Heart Failure Society of America; Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. HFSA 2010 comprehensive heart failure practice guideline. *J Card Fail* 2010;16:e1–e194.
 162. Rosenthal D, Chrisant MR, Edens E, Mahony L, Canter C, Colan S, Dubin A, Lamour J, Ross R, Shaddy R, Addonizio L, Beerman L, Berger S, Bernstein D, Blume E, Boucek M, Checchia P, Dipchand A, Drummond-Webb J, Fricker J, Friedman R, Hallowell S, Jaquiss R, Mital S, Pahl E, Pearce FB, Pearce B, Rhodes L, Rotondo K, Rusconi P, Scheel J, Pal Singh T, Towbin J. International Society for Heart and Lung Transplantation: practice guidelines for management of heart failure in children [published correction appears in *J Heart Lung Transplant*. 2009;28:987]. *J Heart Lung Transplant*. 2004;23:1313–1333.
 163. Malcom J, Arnold O, Howlett JG, Ducharme A, Ezekowitz JA, Gardner M, Giannetti N, Haddad H, Heckman GA, Isaac D, Jong P, Liu P, Mann E, McKelvie RS, Moe GW, Svendsen AM, Tsuyuki RT, O'Halloran K, Ross HJ, Sequeira EJ, White M; Canadian Cardiovascular Society. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure—2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. *Can J Cardiol*. 2008;24:21–40.
 164. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). *Circulation*. 2005;112:e154–e235.
 165. Kremastinos DT. Heart failure in beta-thalassaemia: a local or universal health problem? *Hellenic J Cardiol*. 2007;48:189–190.
 166. Noetzi LJ, Papudis J, Coates TD, Wood JC. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. *Blood*. 2009;114:4021–4026.
 167. Wood JC, Noetzi L, Hyderi A, Joukar M, Coates T, Mittelman S. Predicting pituitary iron and endocrine dysfunction. *Ann NY Acad Sci*. 2010;1202:123–128.
 168. Tsironi M, Korovesis K, Farmakis D, Deftereos S, Aessopos A. Hypoparathyroidism and heart failure in thalassemic patients: a case report. *Pediatr Endocrinol Rev*. 2004;2(suppl 2):310–312.
 169. Tsironi M, Korovesis K, Farmakis D, Deftereos S, Aessopos A. Hypocalcemic heart failure in thalassemic patients. *Int J Hematol*. 2006;83:314–317.
 170. De Sanctis V, Borsari G, Brachi S, Gubellini E, Gamberini MR, Carandina G. A rare cause of heart failure in iron-overload thalassaemic patients—primary hypoparathyroidism. *Georgian Med News* 2008;(156):111–113.
 171. De Sanctis V, Govoni MR, Sprocati M, Marsella M, Conti E. Cardiomyopathy and pericardial effusion in a 7 year-old boy with beta-thalassaemia major, severe primary hypothyroidism and hypoparathyroidism due to iron overload. *Pediatr Endocrinol Rev*. 2008;6(suppl 1):181–184.
 172. De Sanctis V, De Sanctis E, Ricchieri P, Gubellini E, Gilli G, Gamberini MR. Mild subclinical hypothyroidism in thalassaemia major: prevalence, multigated radionuclide test, clinical and laboratory long-term follow-up study. *Pediatr Endocrinol Rev*. 2008;6(suppl 1):174–180.
 173. Banani SA, Omrani GH. Cortisol and adrenocorticotrophic hormone response to surgical stress (splenectomy) in thalassemic patients. *Pediatr Surg Int*. 2000;16:400–403.
 174. Drakonaki E, Papakonstantinou O, Maris T, Vasiliadou A, Papadakis A, Gourtsoyiannis N. Adrenal glands in beta-thalassaemia major: magnetic resonance (MR) imaging features and correlation with iron stores. *Eur Radiol*. 2005;15:2462–2468.
 175. Jaruratanasirikul S, Tanchotikul S, Wongchanchailert M, Laosombat V, Sangsupavanich P, Leetanaporn K. A low dose adrenocorticotropin test (1 microg ACTH) for the evaluation of adrenal function in children with beta-thalassemia receiving hypertransfusion with suboptimal iron-chelating therapy. *J Pediatr Endocrinol Metab*. 2007;20:1183–1188.
 176. Poomthavorn P, Isaradisaikul B, Chuansumrit A, Khlairet P, Sriphrapradang A, Mahachoklertwattana P. High prevalence of “biochemical” adrenal insufficiency in thalassemics: is it a matter of different testings or decreased cortisol binding globulin? *J Clin Endocrinol Metab*. 2010;95:4609–4615.
 177. Scacchi M, Danesi L, Cattaneo A, Valassi E, Pecori G, Radaelli P, Ambrogio A, D'Angelo E, Mirra N, Zanaboni L, Cappellini MD, Cavagnini F. The pituitary-adrenal axis in adult thalassaemic patients. *Eur J Endocrinol*. 2010;162:43–48.
 178. Srivatsa A, Marwaha RK, Muraldharan R, Trehan A. Assessment of adrenal endocrine function in Asian thalassemics. *Indian Pediatr*. 2005;42:31–35.
 179. Vogiatzi MG, Macklin EA, Fung EB, Cheung AM, Vichinsky E, Olivieri N, Kirby M, Kwiatkowski JL, Cunningham M, Holm IA, Lane J, Schneider R, Fleisher M, Grady RW, Peterson CC, Giardina PJ; Thalassemia Clinical Research Network. Bone disease in thalassemia: a frequent and still unresolved problem. *J Bone Miner Res*. 2009;24:543–557.
 180. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, Mammi C, Piepoli M, Fini M, Rosano GM. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. *J Am Coll Cardiol*. 2009;54:919–927.
 181. Iellamo F, Rosano G, Volterrani M. Testosterone deficiency and exercise intolerance in heart failure: treatment implications. *Curr Heart Fail Rep*. 2010;7:59–65.
 182. Maisch B, Alter P, Pankuweit S. Diabetic cardiomyopathy: fact or fiction? *Herz*. 2011;36:102–115.
 183. Claster S, Wood JC, Noetzi L, Carson SM, Hofstra TC, Khanna R, Coates TD. Nutritional deficiencies in iron overloaded patients with hemoglobinopathies. *Am J Hematol*. 2009;84:344–348.
 184. Chiou SS, Chang TT, Tsai SP, Jang RC, Lin SK, Lee SC, Tsai SM, Tsai LY. Lipid peroxidation and antioxidative status in beta-thalassemia major patients with or without hepatitis C virus infection. *Clin Chem Lab Med*. 2006;44:1226–1233.
 185. Kassab-Chekir A, Laradi S, Ferchichi S, Haj Khelil A, Feki M, Amri F, Selmi H, Bejaoui M, Miled A. Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. *Clin Chim Acta*. 2003;338:79–86.
 186. Livrea MA, Tesoriere L, Pintauro AM, Calabrese A, Maggio A, Freisleben HJ, D'Arpa D, D'Anna R, Bongiorno A. Oxidative stress and antioxidant status in beta-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. *Blood*. 1996;88:3608–3614.
 187. Bartfay WJ, Bartfay E. Selenium and glutathione peroxidase with beta-thalassemia major. *Nurs Res*. 2001;50:178–183.
 188. El-Beshlawy A, El Accaoui R, Abd El-Sattar M, Gamal El-Deen MH, Youssry I, Shaheen N, Hamdy M, El-Ghamrawy M, Taher A. Effect of L-carnitine on the physical fitness of thalassemic patients. *Ann Hematol*. 2007;86:31–34.
 189. El-Beshlawy A, Ragab L, Fattah AA, Ibrahim IY, Hamdy M, Makhoulouf A, Aoun E, Hoffbrand V, Taher A. Improvement of cardiac function in thalassemia major treated with L-carnitine. *Acta Haematol*. 2004;111:143–148.

190. Wood JC, Claster S, Carson S, Menteer JD, Hofstra T, Khanna R, Coates T. Vitamin D deficiency, cardiac iron and cardiac function in thalassemia major. *Br J Haematol*. 2008;141:891–894.
191. Otto-Duessel M, Brewer C, Wood JC. Interdependence of cardiac iron and calcium in a murine model of iron overload. *Transl Res*. 2011;157:92–99.
192. Noetzli LJ, Carson S, Coates TD, Wood JC. Revisiting the relationship between vitamin D deficiency, cardiac iron and cardiac function in thalassemia major. *Eur J Haematol*. 2011;86:176–177.
193. Rahav G, Volach V, Shapiro M, Rund D, Rachmilewitz EA, Goldfarb A. Severe infections in thalassaemic patients: prevalence and predisposing factors. *Br J Haematol*. 2006;133:667–674.
194. Bozdogan G, Erdem E, Demirel GY, Yildirmak Y. The role of Treg cells and FoxP3 expression in immunity of β -thalassemia major and β -thalassemia trait patients. *Pediatr Hematol Oncol*. 2010;27:534–545.
195. Gharagozloo M, Karimi M, Amirghofran Z. Double-faced cell-mediated immunity in beta-thalassemia major: stimulated phenotype versus suppressed activity. *Ann Hematol*. 2009;88:21–27.
196. Pardalos G, Kanakoudi-Tsakalidis F, Malaka-Zafiriou M, Tsantali H, Athanasiou-Metaxa M, Kallinikos G, Papaevangelou G. Iron-related disturbances of cell-mediated immunity in multitransfused children with thalassemia major. *Clin Exp Immunol*. 1987;68:138–145.
197. Kanakoudi-Tsakalidis F, Spyrogrou K, Tzafi R, Cassimos C. Effect of blood transfusion on the immune response of children with thalassaemia. *Acta Haematol*. 1977;57:65–73.
198. Kremastinos DT, Tiniakos G, Theodorakis GN, Katritsis DG, Toutouzas PK. Myocarditis in beta-thalassemia major: a cause of heart failure. *Circulation*. 1995;91:66–71.
199. Kremastinos DT, Flevari P, Spyropoulou M, Vrettou H, Tsiapras D, Stavropoulos-Giokas CG. Association of heart failure in homozygous beta-thalassemia with the major histocompatibility complex. *Circulation*. 1999;100:2074–2078.
200. Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, Joussef J, Mitilineou E, Diamanti-Kandaraki E, Meletis J, Karagiorga M. Cardiac status in well-treated patients with thalassemia major. *Eur J Haematol*. 2004;73:359–366.
201. Jessup M, Manno CS. Diagnosis and management of iron-induced heart disease in Cooley's anemia. *Ann NY Acad Sci*. 1998;850:242–250.
202. Vysoulis G, Karpanou E, Kyvelou SM, Tzamou V, Theodosiadis G, Stefanadis C. Ambulatory blood pressure profile in anemic hypertensive patients. *Int J Cardiol*. 2010;145:301–302.
203. Cheung YF, Chow PC, Chan GC, Ha SY. Carotid intima-media thickness is increased and related to arterial stiffening in patients with beta-thalassaemia major. *Br J Haematol*. 2006;135:732–734.
204. Hahalis G, Kremastinos DT, Terzis G, Kalogeropoulos AP, Chrysanthopoulou A, Karakantza M, Kourakli A, Adamopoulos S, Tselepis AD, Grapsas N, Siablis D, Zoumbos NC, Alexopoulos D. Global vasomotor dysfunction and accelerated vascular aging in beta-thalassemia major. *Atherosclerosis*. 2008;198:448–457.
205. Stakos DA, Tavridou A, Margaritis D, Tziakas DN, Kotsianidis I, Chalikias GK, Tsatalas K, Bourikas G, Manolopoulos VG, Boudoulas H. Oxidised low-density lipoprotein and arterial function in beta-thalassemia major. *Eur J Haematol*. 2009;82:477–483.
206. Cheung YF, Ha SY, Chan GC. Ventriculo-vascular interactions in patients with beta thalassaemia major. *Heart*. 2005;91:769–773.
207. Bosi G, Crepaz R, Gambineri MR, Fortini M, Scarcia S, Bonsante E, Pitscheider W, Vaccari M. Left ventricular remodelling, and systolic and diastolic function in young adults with beta thalassaemia major: a Doppler echocardiographic assessment and correlation with haematological data. *Heart*. 2003;89:762–766.
208. Lekawanvijit S, Chattipakorn N. Iron overload thalassaemic cardiomyopathy: iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity. *Can J Cardiol*. 2009;25:213–218.
209. Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, Joussef J, Rombos J, Loukopoulou D. Cardiac involvement in thalassemia intermedia: a multicenter study. *Blood*. 2001;97:3411–3416.
210. Schellhammer PF, Engle MA, Hagstrom JW. Histochemical studies of the myocardium and conduction system in acquired iron-storage disease. *Circulation*. 1967;35:631–637.
211. Hidalgo C, Aracena P, Sanchez G, Donoso P. Redox regulation of calcium release in skeletal and cardiac muscle. *Biol Res*. 2002;35:183–193.
212. Kuryshv YA, Brittenham GM, Fujioka H, Kannan P, Shieh CC, Cohen SA, Brown AM. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes: implications for the arrhythmogenesis of human siderotic heart disease. *Circulation*. 1999;100:675–683.
213. Rose RA, Sellan M, Simpson JA, Izaddoustdar F, Cifelli C, Panama BK, Davis M, Zhao D, Markhani M, Murphy GG, Striessnig J, Liu PP, Heximer SP, Backx PH. Iron overload decreases CaV1.3-dependent L-type Ca^{2+} currents leading to bradycardia, altered electrical conduction, and atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2011;4:733–742.
214. Kaye SB, Owen M. Cardiac arrhythmias in thalassaemia major: evaluation of chelation treatment using ambulatory monitoring. *Br Med J*. 1978;1:342.
215. Mariotti S, Loviselli A, Murenu S, Sau F, Valentino L, Mandas A, Vacquer S, Martino E, Balestrieri A, Lai ME. High prevalence of thyroid dysfunction in adult patients with beta-thalassemia major submitted to amiodarone treatment. *J Endocrinol Invest*. 1999;22:55–63.
216. Russo V, Rago A, Pannone B, Papa AA, Di Meo F, Mayer MC, Spasiano A, Russo MG, Golino P, Calabrò R, Nigro G. Dispersion of repolarization and beta-thalassemia major: the prognostic role of QT and JT dispersion for identifying the high-risk patients for sudden death. *Eur J Haematol*. 2011;86:324–331.
217. Isma'eel H, Shamseddeen W, Taher A, Gharzuddine W, Dimassi A, Alam S, Masri L, Khoury M. Ventricular late potentials among thalassemia patients. *Int J Cardiol*. 2009;132:453–455.
218. Porter JB, Wood J, Olivieri N, Vichinsky EP, Taher A, Neufeld E, Giardina P, Thompson A, Moore B, Evans P, Kim HY, Macklin EA, Trachtenberg F; for the Thalassemia Clinical Research Network. Treatment of heart failure in adults with thalassaemia major: response in patients randomised to deferoxamine with or without deferiprone. *J Cardiovasc Magn Reson*. 2013;15:38.
219. Porter JB, Davis BA. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. *Best Pract Res Clin Haematol*. 2002;15:329–368.
220. Forni GL, Puntoni M, Boeri E, Terenzani L, Balocco M. The influence of treatment in specialized centers on survival of patients with thalassemia major. *Am J Hematol*. 2009;84:317–318.
221. Tsironi M, Deftereos S, Andriopoulos P, Farmakis D, Meletis J, Aessopos A. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. *Eur J Haematol*. 2005;74:84–85.
222. Porcu M, Landis N, Salis S, Corda M, Orrù P, Serra E, Usai B, Matta G, Galanello R. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report. *Eur J Heart Fail*. 2007;9:320–322.
223. Fabio G, Minonzio F, Delbini P, Bianchi A, Cappellini MD. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). *Blood*. 2007;109:362–364.
224. Tavecchia L, Masera N, Russo P, Cirò A, Vincenzi A, Vimercati C, Masera G. Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone. *Haematologica*. 2006;91(suppl):ECR19.
225. Wu KH, Chang JS, Tsai CH, Peng CT. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. *Ann Hematol*. 2004;83:471–473.
226. Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferrioxamine alone. *Blood Cells Mol Dis*. 2010;45:136–139.
227. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA; UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure [published correction appears in *J Am Coll Cardiol*. 2007;49:1136]. *J Am Coll Cardiol*. 2007;49:675–683.
228. Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. *J Am Coll Cardiol*. 2012;59:2145–2153.
229. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E; Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. *N Engl J Med*. 2012;367:2296–2304.
230. Puskasich MA, Runyon MS, Trzeciak S, Kline JA, Jones AE. Effect of glucose-insulin-potassium infusion on mortality in critical care

- settings: a systematic review and meta-analysis. *J Clin Pharmacol*. 2009;49:758–767.
231. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy JP, Paterson I, Filipchuk NG, Kumar A, Pauschinger M, Liu P; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. *J Am Coll Cardiol*. 2009;53:1475–1487.
 232. Olivieri NF, Liu PP, Sher GD, Daly PA, Greig PD, McCusker PJ, Collins AF, Francombe WH, Templeton DM, Butany J. Brief report: combined liver and heart transplantation for end-stage iron-induced organ failure in an adult with homozygous beta-thalassemia. *N Engl J Med*. 1994;330:1125–1127.
 233. Perrimond H, Michel G, Orsini A, Kreitmann B, Metras D. First report of a cardiac transplantation in a patient with thalassaemia major. *Br J Haematol*. 1991;78:467.
 234. Koerner MM, Tenderich G, Minami K, zu Knyphausen E, Mannebach H, Kleesiek K, Meyer H, Koerfer L. Heart transplantation for end-stage heart failure caused by iron overload. *Br J Haematol*. 1997;97:293–296.
 235. Caines AE, Kpodonu J, Massad MG, Chaer R, Evans A, Lee JC, Geha AS. Cardiac transplantation in patients with iron overload cardiomyopathy. *J Heart Lung Transplant*. 2005;24:486–488.
 236. Short EM, Winkle RA, Billingham ME. Myocardial involvement in idiopathic hemochromatosis: morphologic and clinical improvement following venesection. *Am J Med*. 1981;70:1275–1279.
 237. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. *Blood*. 2003;101:91–96.
 238. Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, Paley C, Coates TD. Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial. *Haematologica*. 2011;96:1055–1058.
 239. Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, Paley C, Coates TD. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. *Blood*. 2010;116:537–543.
 240. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. *Lancet*. 2002;360:516–520.
 241. Porter JB, Abeyasinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. *Blood*. 1996;88:705–713.
 242. Zanninelli G, Breuer W, Cabantchik ZI. Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients. *Br J Haematol*. 2009;147:744–751.
 243. Piga A, Longo F, Duca L, Roggero S, Vinciguerra T, Calabrese R, Hershko C, Cappellini MD. High nontransferrin bound iron levels and heart disease in thalassemia major. *Am J Hematol*. 2009;84:29–33.
 244. Porter JB. Optimizing iron chelation strategies in beta-thalassaemia major. *Blood Rev*. 2009;23(suppl 1):S3–S7.
 245. Kwiakowski JL. Oral iron chelators. *Hematol Oncol Clin North Am*. 2010;24:229–248.
 246. Brittenham GM. Iron-chelating therapy for transfusional iron overload. *N Engl J Med*. 2011;364:146–156.
 247. Pepe A, Lombardi M, Positano V, Cracolici E, Capra M, Malizia R, Prossomariti L, De Marchi D, Midiri M, Maggio A. Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. *Eur J Haematol*. 2006;76:183–192.
 248. Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, Putti MC, Lippi A, Romeo MA, Bisconte MG, Filosa A, Caruso V, Quarta A, Pitrolo L, Missere M, Midiri M, Rossi G, Positano V, Lombardi M, Maggio A. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. *Haematologica*. 2011;96:41–47.
 249. Piga A, Gaglioti C, Fogliaccio E, Tricci F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. *Haematologica*. 2003;88:489–496.
 250. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. *Blood*. 2006;107:3733–3737.
 251. Ha SY, Mok AS, Chu WC, Raskalkar DD, Cheuk DK, Chiang AK, Ho MH, Chan GC. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*. *Hemoglobin*. 2009;33:323–331.
 252. Ha SY, Mok AS, Chu WC, Rasalkar DD, Cheuk DK, Chiang AK, Ho MH, Chan GC. Intermediate-term evaluation of a practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*. *Hemoglobin*. 2011;35:199–205.
 253. European Medicines Agency Web site. Summary of product characteristics for Ferriprox. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000236/WC500022050.pdf. Accessed May 23, 2013.
 254. Smith GC, Alpendurada F, Carpenter JP, Alam MH, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Westwood MA, Galanello R, Roughton M, Pennell DJ. Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. *J Cardiovasc Magn Reson*. 2011;13:34.
 255. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Continued improvement in myocardial T2* over two years of deferasirox therapy in β -thalassaemia major patients with cardiac iron overload. *Haematologica*. 2011;96:48–54.
 256. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β -thalassaemia major. *Haematologica*. 2012;97:842–848.
 257. Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, Paley C, Coates TD. Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial. *Am J Hematol*. 2010;85:818–819.
 258. Pathare A, Taher A, Daar S. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. *Ann Hematol*. 2010;89:405–409.
 259. Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Beloul K, Elalfy M, Yesilipek A, Kiliç Y, Lawniczek T, Habr D, Weisskopf M, Zhang Y, Aydinok Y. A multicenter, randomized, open-label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with β -thalassaemia major and iron overload (CORDELIA). *Blood (ASH Annual Meeting Abstracts)*. 2012;120:Abstract 2124.
 260. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. *Br J Haematol*. 1998;103:361–364.
 261. Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. *Haematologica*. 2003;88:1423–1425.
 262. Evans P, Kayyali R, Hider RC, Eccleston J, Porter JB. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. *Transl Res*. 2010;156:55–67.
 263. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. *Br J Haematol*. 2010;148:466–475.
 264. Jetsrisuparb A, Komvilaisak P, Wiangnon S, Jetsrisuparb C. Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years. *J Pediatr Hematol Oncol*. 2010;32:400–403.
 265. Farmaki K, Tzoumari I, Pappa C. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. *Blood Cells Mol Dis*. 2011;47:33–40.
 266. Alpendurada F, Smith GC, Carpenter JP, Nair SV, Tanner MA, Banya W, Dessi C, Galanello R, Walker JM, Pennell DJ. Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major. *J Cardiovasc Magn Reson*. 2012;14:8.
 267. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. *Br J Haematol*. 2003;121:187–189.
 268. Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, Kolnagou A, Angastiniotis M. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. *Haematologica*. 2009;94:1777–1778.
 269. Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW. Combined iron chelation therapy. *Ann NY Acad Sci*. 2010;1202:79–86.

270. Berdoukas V, Carson S, Nord A, Dongelyan A, Gavin S, Hofstra TC, Wood JC, Coates T. Combining two orally active iron chelators for thalassemia. *Ann Hematol*. 2010;89:1177–1178.
271. Lal A, Porter J, Sweeters N, Ng V, Evans P, Neumayr L, Kurio G, Harmatz P, Vichinsky E. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. *Blood Cells Mol Dis*. 2013;50:99–104.
272. Maggio A, Vitranò A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassemia major patients: a randomized clinical trial. *Br J Haematol*. 2009;145:245–254.
273. Pennell DJ, Carpenter JP, Roughton M, Cabantchik Z. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. *J Cardiovasc Magn Reson*. 2011;13:45.
274. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, Galimberti M, Polchi P, Lucarelli G. Hepatic iron concentration and total body iron stores in thalassemia major [published correction appears in *N Engl J Med*. 2000;343:1740]. *N Engl J Med*. 2000;343:327–331.
275. Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, Ripalti M, Sodani P, Tomassoni S, Visani G, Lucarelli G. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. *Blood*. 2002;100:17–21.
276. Maggio A, Vitranò A, Lucania G, Capra M, Cuccia L, Gagliardotto F, Pitrolo L, Prossomariti L, Filosa A, Caruso V, Gerardi C, Campisi S, Cianciulli P, Rizzo M, D'Ascola G, Ciancio A, Di Maggio R, Calvaruso G, Pantalone GR, Rigano P. Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients. *Am J Hematol*. 2012;87:732–733.
277. Modell B, Letsky EA, Flynn DM, Peto R, Weatherall DJ. Survival and desferrioxamine in thalassemia major. *Br Med J (Clin Res Ed)*. 1982;284:1081–1084.
278. Ceci A, Baiardi P, Catapano M, Felisi M, Cianciulli P, De Sanctis V, Del Vecchio GC, Magnano C, Meo A, Maggio A. Risk factors for death in patients with beta-thalassemia major: results of a case-control study. *Haematologica*. 2006;91:1420–1421.
279. Maggio A, Vitranò A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. *Blood Cells Mol Dis*. 2009;42:247–251.
280. Savona-Ventura C, Bonello F. Beta-thalassemia syndromes and pregnancy. *Obstet Gynecol Surv*. 1994;49:129–137.
281. Tuck SM, Jensen CE, Wonke B, Yardumian A. Pregnancy management and outcomes in women with thalassemia major. *J Pediatr Endocrinol Metab*. 1998;11(suppl 3):923–928.
282. Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with Thalassemia Major. *Pediatr Endocrinol Rev*. 2007;5:642–648.
283. Origa R, Piga A, Quarta G, Forni GL, Longo F, Melpignano A, Galanello R. Pregnancy and beta-thalassemia: an Italian multicenter experience. *Haematologica*. 2010;95:376–381.
284. Ansari S, Azarkeivan A, Kivan AA, Tabaroki A. Pregnancy in patients treated for beta thalassemia major in two centers (Ali Asghar Children's Hospital and Thalassemia Clinic): outcome for mothers and newborn infants [published correction appears in *Pediatr Hematol Oncol*. 2008;25:163]. *Pediatr Hematol Oncol*. 2006;23:33–37.
285. Bajoria R, Chatterjee R. Current perspectives of fertility and pregnancy in thalassemia. *Hemoglobin*. 2009;33(suppl 1):S131–S135.
286. Singer ST, Sweeters N, Vega O, Higa A, Vichinsky E, Cedars M. Fertility potential in thalassemia major women: current findings and future diagnostic tools. *Ann NY Acad Sci*. 2010;1202:226–230.
287. Leung TY, Lao TT. Thalassemia in pregnancy. *Best Pract Res Clin Obstet Gynaecol*. 2012;26:37–51.
288. Skordis N, Christou S, Koliou M, Pavlides N, Angastiniotis M. Fertility in female patients with thalassemia. *J Pediatr Endocrinol Metab*. 1998;11(suppl 3):935–943.
289. Nassar AH, Usta IM, Rechdan JB, Koussa S, Inati A, Taher AT. Pregnancy in patients with beta-thalassemia intermedia: outcome of mothers and newborns. *Am J Hematol*. 2006;81:499–502.
290. Borgna-Pignatti C. Surviving with thalassemia major: the Italian experience. *Pediatr Hematol Oncol*. 2007;24:75–78.
291. Schwartz KA, Li Z, Schwartz DE, Cooper TG, Braselton WE. Earliest cardiac toxicity induced by iron overload selectively inhibits electrical conduction. *J Appl Physiol*. 2002;93:746–751.
292. Ghader FR, Kousarian M, Farzin D. High-dose deferoxamine treatment (intravenous) for thalassemia patients with cardiac complications. *East Mediterr Health J*. 2007;13:1053–1059.
293. Lombardo T, Ferro G, Frontini V, Percolla S. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration. *Am J Hematol*. 1996;51:90–92.
294. Fogel RI, Prystowsky EN. Management of malignant ventricular arrhythmias and cardiac arrest. *Crit Care Med*. 2000;28(suppl):N165–N169.
295. Ho KM. Intravenous magnesium for cardiac arrhythmias: jack of all trades. *Magnes Res*. 2008;21:65–68.
296. Ho KM, Sheridan DJ, Paterson T. Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis. *Heart*. 2007;93:1433–1440.
297. Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassemia and sickle cell anemia as paradigms of hypercoagulability. *Br J Haematol*. 2007;139:3–13.
298. Pattanapanyasat K, Gonwong S, Chaichompoo P, Noulis E, Lerwana S, Sukapirom K, Siritanaratkul N, Fucharoen S. Activated platelet-derived microparticles in thalassemia. *Br J Haematol*. 2007;136:462–471.
299. Eldor A, Durst R, Hy-Am E, Goldfarb A, Gillis S, Rachmilewitz EA, Abramov A, MacLough J, Godefray YC, De Raucourt E, Guillin MC. A chronic hypercoagulable state in patients with beta-thalassemia major is already present in childhood. *Br J Haematol*. 1999;107:739–746.
300. Nault I, Miyazaki S, Forclaz A, Wright M, Jadidi A, Jaïs P, Hocini M, Haïssaguerre M. Drugs vs. ablation for the treatment of atrial fibrillation: the evidence supporting catheter ablation. *Eur Heart J*. 2010;31:1046–1054.
301. Pappone C, Santinelli V. Atrial fibrillation ablation: state of the art. *Am J Cardiol*. 2005;96(12A):59L–64L.
302. Ehlers KH, Levin AR, Markenson AL, Marcus JR, Klein AA, Hilgartner MW, Engle MA. Longitudinal study of cardiac function in thalassemia major. *Ann NY Acad Sci*. 1980;344:397–404.
303. Wilkoff BL, Bello D, Taborsky M, Vymazal J, Kanal E, Heuer H, Hecking K, Johnson WB, Young W, Ramza B, Akhtar N, Kuepper B, Hunold P, Luechinger R, Puererfellner H, Duru F, Gotte MJ, Sutton R, Sommer T; EnRhythm MRI SureScan Pacing System Study Investigators. Magnetic resonance imaging in patients with a pacemaker system designed for the magnetic resonance environment. *Heart Rhythm*. 2011;8:65–73.
304. Di Marco V, Capra M, Angelucci E, Borgna-Pignatti C, Telfer P, Harmatz P, Kattamis A, Prossomariti L, Filosa A, Rund D, Gamberini MR, Cianciulli P, De Montalembert M, Gagliardotto F, Foster G, Grangè JD, Cassarà F, Iacono A, Cappellini MD, Brittenham GM, Prati D, Pietrangeli A, Craxi A, Maggio A; Italian Society for the Study of Thalassemia and Hemoglobinopathies; Italian Association for the Study of the Liver. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. *Blood*. 2010;116:2875–2883.
305. Dwyre DM, Fernando LP, Holland PV. Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century. *Vox Sang*. 2011;100:92–98.
306. Perifanis V, Tziomalos K, Tsatra I, Karyda S, Patsiaoura K, Athanassiou-Metaxa M. Prevalence and severity of liver disease in patients with β thalassemia major: a single-institution fifteen-year experience. *Haematologica*. 2005;90:1136–1138.
307. Borgna-Pignatti C, Vergine G, Lombardo T, Cappellini MD, Cianciulli P, Maggio A, Renda D, Lai ME, Mandas A, Forni G, Piga A, Bisconte MG. Hepatocellular carcinoma in the thalassemia syndromes. *Br J Haematol*. 2004;124:114–117.
308. Mancuso A, Sciarrino E, Renda MC, Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassemia. *Hemoglobin*. 2006;30:119–124.
309. Restivo Pantalone G, Renda D, Valenza F, D'Amato F, Vitranò A, Cassarà F, Rigano P, Di Salvo V, Giangreco A, Bevacqua E, Maggio A. Hepatocellular carcinoma in patients with thalassemia syndromes: clinical characteristics and outcome in a long term single centre experience. *Br J Haematol*. 2010;150:245–247.

310. Fragatou S, Tsourveloudis I, Manesis G. Incidence of hepatocellular carcinoma in a thalassemia unit. *Hemoglobin*. 2010;34:221–226.
311. Chronic Kidney Disease Prognosis Consortium; Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet*. 2010;375:2073–2081.
312. Sumboonnanonda A, Malasit P, Tanphaichitr VS, Ong-ajyooth S, Sunthornchart S, Pattanakitsakul S, Petrarat S, Assateerawatt A, Vongjirad A. Renal tubular function in beta-thalassemia. *Pediatr Nephrol*. 1998;12:280–283.
313. Aldudak B, Karabay Bayazit A, Noyan A, Ozel A, Anarat A, Sasmaz I, Kilinc Y, Gali E, Anarat R, Dikmen N. Renal function in pediatric patients with beta-thalassemia major. *Pediatr Nephrol*. 2000;15:109–112.
314. Smolkin V, Halevy R, Levin C, Mines M, Sakran W, Ilia K, Koren A. Renal function in children with beta-thalassemia major and thalassemia intermedia. *Pediatr Nephrol*. 2008;23:1847–1851.
315. Quinn CT, Johnson VL, Kim HY, Trachtenberg F, Vogiatzi MG, Kwiatkowski JL, Neufeld EJ, Fung E, Oliveri N, Kirby M, Giardina PJ; Thalassemia Clinical Research Network. Renal dysfunction in patients with thalassaemia. *Br J Haematol*. 2011;153:111–117.
316. Bhandari S, Galanello R. Renal aspects of thalassaemia a changing paradigm. *Eur J Haematol*. 2012;89:187–197.
317. Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. *Drug Metab Rev*. 1999;31:971–997.
318. Ueda N. Oxidant mechanisms in acute renal failure. In Molitoris B, Finn W, eds. *Acute Renal Failure: A Companion to Brenner & Rector's The Kidney*. Philadelphia, PA: WB Saunders; 2001:60–77.
319. Koren G, Bentur Y, Strong D, Harvey E, Klein J, Bauman R, Spielberg SP, Freedman MH. Acute changes in renal function associated with deferoxamine therapy. *Am J Dis Child*. 1989;143:1077–1080.
320. Cianciulli P, Sorrentino F, Forte L, Palombi M, Papa G, Meloni C, Taccone Gallucci M, Casciani CU. Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis. *Haematologica*. 1992;77:514–515.
321. Cianciulli P, Sollecito D, Sorrentino F, Forte L, Gilardi E, Massa A, Papa G, Carta S. Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy. *Kidney Int*. 1994;46:467–470.
322. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A; EPIC Study Investigators. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. *Haematologica*. 2010;95:557–566.
323. Brosnahan G, Gokden N, Swaminathan S. Acute interstitial nephritis due to deferasirox: a case report. *Nephrol Dial Transplant*. 2008;23:3356–3358.
324. Papadopoulos N, Vasiliki A, Aloizos G, Tapinis P, Kikilas A. Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major. *Ann Pharmacother*. 2010;44:219–221.
325. Vlachaki E, Chatzinikolaou K, Bekiari E, Klonizakis F, Tsapas A. Is deferasirox implicated in multiple organ failure in a patient with homozygous β -thalassemia? *Angiology*. 2011;62:346–348.
326. Rheault MN, Bechtel H, Neglia JP, Kashtan CE. Reversible Fanconi syndrome in a pediatric patient on deferasirox. *Pediatr Blood Cancer*. 2011;56:674–676.
327. Yacovovich J, Stark P, Barzilai-Birenbaum S, Krause I, Pazgal I, Yaniv I, Tamary H. Acquired proximal renal tubular dysfunction in β -thalassemia patients treated with deferasirox. *J Pediatr Hematol Oncol*. 2010;32:564–567.
328. Jensen JH, Tang H, Tosti CL, Swaminathan SV, Nunez A, Hultman K, Szulc KU, Wu EX, Kim D, Sheth S, Brown TR, Brittenham GM. Separate MRI quantification of dispersed (ferritin-like) and aggregated (hemosiderin-like) storage iron. *Magn Reson Med*. 2010;63:1201–1209.
329. Carpenter JP, Grasso AE, Porter JB, Shah F, Dooley J, Pennell DJ. On myocardial siderosis and left ventricular dysfunction in hemochromatosis. *J Cardiovasc Magn Reson*. 2013;15:24.
330. Amlodipine use in the prevention and treatment of iron overload in patients with thalassemia major (AnloThal). <http://www.clinicaltrials.gov/show/NCT01395199>. May 23, 2013.

